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 Mitochondrial Encephalomyopathies are a group of disorders with common symptoms such as 
neurological, cardiac, and muscular dysfunctions. Mutations in ATP6, a protein-coding gene in 
the mitochondria genome, can lead to NARP, MILS, or FBSN diseases. ATP6 encodes a protein 
subunit of the ATP synthase, also known as complex V. Currently, there is no cure for patients 
with ATP6 mutations, and pharmacotherapies provide limited benefits. Because manipulation of 
mitochondrial genome is extremely difficult, allotopic expression of ATP6 – specifically, 
expressing the mitochondrially-encoded ATP6 gene in the nucleus – has been championed as a 
potential gene therapy strategy. Efficacies of allotopic rescue in in vitro systems have been 
controversial, with some studies showing the restoration of ATP synthase activity and some 
showing the lack of any rescue effects. We have isolated a Drosophila strain with a missense 
mutation in ATP6. The phenotypes of this mutant ATP6 strain have been characterized and are 
very similar to those of human patients, making it an excellent model for diseases caused by 
ATP6 mutation. The overarching goal of this dissertation is to import nucleus-encoded ATP6 
protein into the mitochondria. This work examines the efficacies of multiple strategies in 
enhancing the functional outcomes of the first animal model with a stable and endogenous ATP6 
mutation and shows that algal ATP6 protein provides the most promising rescue results. 
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1.0  INTRODUCTION  
Mitochondrial Encephalomyopathy (ME) is a relatively common large group of syndromes that 
is currently incurable. The type of ME that we focus on is caused by ATP6 mutation. ATP6 is a 
subunit of ATP synthase, also known as complex V, which is involved in generating the energy 
molecule ATP in oxidative phosphorylation. Mutations in ATP6 commonly manifest as 
neurological, cardiac, and muscular dysfunctions, and variations in mutant mitochondrial DNA 
(mtDNA) loads lead to a range of severity in symptoms and age of disease onset. Studying ATP6 
has proven challenging due to the lack of a rigorous animal model. The Palladino lab has isolated 
a Drosophila strain ATP6[1] that has a stable, endogenous ATP6 mutation. Previous 
characterization of this mutant has shown that ATP6[1] expresses disease phenotypes that are 
very similar to those in human patients and serves as an excellent model to study disease 
pathogenesis and develop gene therapy approaches for ATP6 mutation. For my dissertation, I 
examined the efficacy of allotopic expression – expressing mitochondrial-DNA-encoded ATP6 
gene in the nucleus – and import of the engineered, functional ATP6 protein into the 
mitochondria to rescue the ATP6[1] mutant flies. The functional readouts of such rescue include 
measures of longevity and locomotor function, specifically recovery time after mechanical stress 
test. We have utilized different strategies including expressing Chlamydomonas reinhardtii 
ATP6 gene, examining different mitochondrial targeting sequences (MTSs), attaching SOD2 3’ 
untranslated region (3’UTR) or OXA1 3’UTR to mRNA, utilizing suboptimally-encoded codons, 
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employing translational inhibitors (TLIs), and overexpressing factors that are involved in 
mitochondrial biogenesis (AMPK, PGC1-α, and DSP1), mitophagy (ATG1), mitochondrial 
protein folding/degradation (mtHSP70), and mitochondrial protein import (OXA1). 
1.1 MITOCHONDRIAL OVERVIEW 
1.1.1 Endosymbiotic Theory and the Mitochondrial Genome 
Endosymbiotic Theory proposes that mitochondria evolved from free-living bacteria and 
developed a symbiotic relationship within the host eukaryotic cells [1]. The theory is supported 
by the fact that mitochondria have their own genomes and a distinct translation system [2]. Many 
essential proteins for mitochondria and chloroplasts are encoded by the nucleus [3, 4], suggesting 
that during evolution many genes have translocated from ancestral organelles (mitochondria and 
chloroplasts) to the nucleus [5, 6]. mtDNA sequences have also been discovered in the nuclear 
genome [7]. The detailed mechanism of such transfer remains unclear, but there are two major 
theories. The “direct DNA transfer” theory suggests that recombination occurs between escaped 
organelle DNA and nuclear DNA [5]. The most impressive evidence supporting this theory 
points to the entire mitochondrial genome showing up in the second chromosome of the 
Arabidopsis nuclear genome [8]. The “cDNA transfer” suggests that cDNAs of organelle 
mRNAs are transferred to the nucleus. Genes present in the mitochondrial genomes of some 
plants are often found in the nuclear genomes of related species but without the introns [9-12]. 
Also, functional copies of mitochondrial genes are found in the nuclear genome of related 
species [13, 14]. Indeed, with the outflow of genetic content, human mtDNA 16.5-kilobase (kb) 
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genome is exceedingly small, comparing to the 3 million-kb nuclear genome. The double-
stranded mitochondrial genome is circular and has only 13 established protein-coding genes, all 
of which are involved in the electron transport chain complexes supporting OXPHOS (oxidative 
phosphorylation). There are multiple mitochondria in a cell and multiple mitochondrial genomes 
within a mitochondrion [15], ranging from 2-10 mtDNA genomes in each mitochondrion and up 
to hundreds of mitochondrial genomes in muscle and nerve cells where energy demand is high 
[16]. 
1.1.2 Maternal Inheritance 
mtDNA is maternally inherited [17, 18]. Uniparental inheritance is conserved in many species, 
including Drosophila melanogaster [19]. There are many theories regarding the prevalence of 
uniparental inheritance [20]. It has been suggested that by limiting the spread of potentially 
deleterious mutant genes, common in mitochondria due to oxidative damage, from parent to 
offspring, a wider spread throughout the population can be prevented [20, 21]. However, 
theoretical evolutionary advantages do not necessarily explain the prevalence of uniparental 
inheritance. It is suggested that uniparental inheritance may have little value to organisms, and 
the prevalence of uniparental inheritance is a result of transition between biparental and 
uniparental species, and that selection of other traits such as oogamy may lead to uniparental 
inheritance as a secondary result [20].  
 
Regarding maternal inheritance specifically, it has been suggested that paternal 
mitochondria within sperms do enter zygotes and co-exist with maternal mitochondria briefly, 
but they are eliminated and not transmitted to the offspring [22]. The dilution model asserts that 
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the mitochondrial copy number is so low that it cannot be detected in the offspring with low-
resolution experiments [23], while active degradation model suggests that paternal mitochondria 
are selectively eliminated to prevent transmission to the offspring [24]. Ubiquitin-mediated 
degradation of mitochondria has been demonstrated in monkeys and cows [25, 26], while 
fertilization can trigger paternal mtDNA autophagy in Caenorhabditis elegans [27, 28]. 
However, autophagy is not involved in sperm degradation in mice [29], suggesting species 
specificity. In Drosophila, mitochondria in sperm undergo physical transformation during 
spermatogenesis and endonuclease G is responsible for the mtDNA degradation during sperm 
fusion/elongation [30]. A second mechanism is also utilized that involves cellular remodeling to 
trim the mitochondrial mass, which ultimately is extruded as waste in the apical end of the sperm 
tail to remove residual sperm mtDNA [30]. The practical implication of maternal inheritance is 
that the offspring will not be affected if the paternal parent has a mitochondrial disease 
(symptomatic) or carries a mutation in his mitochondrial genome (asymptomatic). However, the 
offspring may or may not be affected if the maternal parent has a mitochondrial disease or carries 
a mutation in her mitochondrial genome (Figure 1), depending on the percentage of 
mitochondrial genome with the mutation the offspring has inherited (See Section 1.1.3). 
1.1.3 Heteroplasmy and the Threshold Effect 
Heteroplasmy describes a mixture of mtDNA sequences within a cell. When a single mtDNA 
sequence exists within a cell, and this state is called homoplasmy. When two or more mtDNA 
sequences exist in the cell, it is called heteroplasmy. Interestingly, a transgenic mouse strain with 
similar proportions of NZB and 129S6 “normal” mtDNA in a nuclear C57BL/6J background 
experiences reduced proportion of NZB mtDNA in successive maternal generations [31]. 
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Incompatibility between C57BL/6J nuclear DNA and NZB mtDNA has been ruled out as 
measured by fertility and survivorship, and it is unclear why a particular mtDNA is selected 
against [31]. Mouse strain with heteroplasmic NZB and 129S6 mtDNA experiences reduced 
food intake and activity, increased anxiety-related behavior, and learning/memory impairment, 
but these phenotypes are not observed in mouse strains with either homoplasmic NZB mtDNA or 
homoplasmic 129S6 mtDNA [31]. This suggests that there is a mechanism to eliminate 
heteroplasmy, even if both of the mtDNA types are non-pathogenic. It is unclear why and how it 
is performed. 
 
When heteroplasmy exists in a patient and one of the mtDNA types carries a pathogenic 
mutation, the percentage of heteroplasmy is an important determinant as to whether a patient 
becomes symptomatic and disease severity. The minimum percentage of mutant mitochondrial 
genomes required to cause dysfunction in a specific tissue is known as the threshold [15, 32]. 
The percentage of the mitochondria with mutant mtDNA, also known as the mutant load, is 
positively correlated to the severity of the symptoms and negatively with the age of disease 
onset. For example, patients with 70-90% heteroplasmy of mutant ATP6 usually develop 
Neuropathy, Ataxia, Retinitis Pigmentosa (NARP) while patients with >90% heteroplasmy 
usually develop Maternally Inherited Leigh Syndrome (MILS), a much more severe phenotype 
[33-37]. NARP has a more moderate course and patients usually survive into adulthood, while 
MILS progresses more rapidly and childhood deaths are common. However, patients with less 
than 70% heteroplasmy are often asymptomatic and lead normal lives (Figure 2). Threshold to 
clinical symptoms is not fixed but depends on the tissue type and the energy demand [15]. This 
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dramatic threshold effect suggests that modifying the ratio of normal to mutant mtDNA may be 
sufficient to provide functional cures to many mitochondrial diseases. 
 6 
  
Figure 1. Maternal Inheritance in Mitochondrial Diseases. 
(A). The paternal parent carries a mutation in his mitochondrial genome; however, the 
offspring will not be affected because they inherit mitochondria from the maternal parent only. 
(B). The maternal parent carries a mutation in her mitochondrial genome. The offspring may 
develop a mitochondrial disease, depending on the percentage of mitochondrial genome carrying 
the mutation he/she has inherited. 
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 Figure 2. Heteroplasmy Determines the Severity of Mitochondrial Diseases. 
In this example, the maternal parent carries a 30% heteroplasmy and is asymptomatic. 
Whether the offspring develops mitochondrial diseases depends on the percentage of 
mitochondrial genome with the mutation he/she has inherited. If the offspring has inherited more 
than 70% of the mitochondrial genome with an ATP6 mutation, he/she will develop NARP. If an 
offspring has inherited more than 90% of the mitochondrial genome with an ATP6 mutation, 
he/she will develop MILS. 
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 1.1.4 Mitotic Segregation 
During cell division, the daughter cells may experience a shift in the percentage of mutant 
mtDNA [15]. This shift can occur within an individual or between generations. Patients 
diagnosed with ME, lactic acidosis, and stroke-like episodes (MELAS) show a decline in mutant 
load in blood samples, suggesting that mutant mtDNA is selected against in rapidly dividing red 
blood cells during aging [38]. One clinical example of mitotic segregation is children surviving 
Pearson’s syndrome may develop Kearns-Sayre-syndrome (KSS) in early adulthood [39]. 
Pearson’s syndrome and KSS are characterized by mtDNA deletions [40-42]. Hallmark of 
Pearson’s syndrome is that the patient, usually at infancy, will develop sideroblastic anemia [43]. 
If the patient survives this blood disorder, the patient’s status usually improves with decreasing 
mtDNA deletion probably due to the rapid turnover of red blood cells. However, the patient may 
develop KSS later in life because mtDNA deletion in their muscles, which are post-mitotic 
tissues, can increase with time [39]. These examples demonstrate how the symptoms of 
mitochondrial disorders can change depending on the heteroplasmy and the tissues affected. 
1.1.5 Mitochondrial Genetic Code 
Mitochondria not only have their own genomic DNA but also utilize codons that are different 
from the mammalian universal nuclear genetic code [44], probably reflecting their origins as 
independent entities. In the universal code, AGA and AGG are translated as arginine, and it was 
thought that these two codons had become mitochondrial stop codons during vertebrate evolution 
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[45]. However, it has been shown that at least in human mitochondrial ribosomes -1 frameshift 
occurs at the AGA and AGC codons to terminate the two open reading frames (ORFs) in 
MTCO1 and MTND6, respectively, so both ORFs terminate using the standard UAG codon [46]. 
However, it is not known if this applies to Drosophila. The practical implication of different 
genetic codes between mitochondria and nucleus is that “recoding” - modification of 
mitochondrial gene sequence - is necessary if the mitochondrial gene is to be expressed in the 
nucleus for gene therapy purpose [15]. 
1.2 MITOCHONDRIAL PROTEIN IMPORT OVERVIEW 
1.2.1 Mitochondrial Targeting Sequences (MTSs) 
Also known as Mitochondrial Targeting Signals, these sequences direct the cytosolic precursors 
of mitochondrial proteins to the mitochondria [47]. MTSs are generally 20-50 amino acids long, 
with a range from 10-80 residues [48]. The primary structures of MTSs are not conserved among 
closely related orthologs [49] and no homology is found among proteins that are targeted 
towards the same mitochondrial compartment [50], but MTSs tend to have mostly positive 
charges and very few if any negative charges [47]. Notably, they have the potential to form 
amphipathic helices in membranes, with one hydrophobic face and one positively charged face 
[51]. Most of these signals identified are located in the N-termini [52], but there are many 
internal targeting signals as well and their nature remains unclear [49] due to the intrinsic 
difficulties in isolating such signals without compromising the entire protein conformations [47]. 
There is at least one protein, yeast DNA helicase Hmi1, that has a naturally encoded C-termini 
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MTS and the protein is translocated from the C to N orientation [53]. Attaching a N-terminal 
MTS to the C-terminus of a protein artificially is sufficient to translocate the protein into the 
mitochondria in a C to N fashion [54]. Once the protein arrives at its destination, the MTS will 
be cleaved by a specific peptidase. There are four major types of MTS peptidase, with 
mitochondrial processing peptidase (MPP) cleaving most of the precursor proteins [55]. MPP 
resides in matrix and is a heterodimer consists of the larger α-MPP (Mas2) and the smaller β-
MPP (Mas1) [55]. The catalytic activity of the protease resides in a zinc-binding motif of a 
subunit in β-MPP, and any mutation in the zinc-binding motif abolishes the catalytic activity 
[55]. Effort has been made to identify cleavage sites on the mitochondrial proteins; however, 
there is a high degree of degeneracy among cleavage sites of the proteins that have been 
analyzed, making reliable prediction difficult [56]. Inner membrane peptidase (IMP) is a 
heterodimer, consisting of two catalytic units, Imp1 and Imp2, and an accessory protein Som1 
that has no enzymatic activity [57-59]. Imp1 and Imp2 have nonoverlapping substrate 
specificities and Imp2 is needed for stable expression of Imp1 protein [60]. IMP is responsible 
for cleaving the MTS from proteins that have their N-terminal MTS exposed in the inner 
membrane space [61]. It can cleave MTS of Cox2 independently of MPP [62] but can also 
process protein precursor further after the precursor has been processed by MPP [63]. However, 
only four substrates for Imp1 and one substrate for Imp2 have been identified [56]. Octapeptidyl 
aminopeptidase 1 (Oct1), formerly known as mitochondrial intermediate peptidase (MIP), is a 
metalloprotease that exists in monomeric form in the matrix [56]. It cleaves its substrate by 
removing an additional octapeptide only after the substrate has been processed by MPP [64]. 
Intermediate cleaving peptidase 55 (Icp55), like Oct1, resides in the matrix and cleaves residues 
after MPP processing [65]. However, instead of removing ocatpeptide, Icp55 cleaves single 
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phenylalanine, leucine, and tyrosine. By comparing Icp55 and Oct1 substrates at intermediate 
stages and upon full maturation, it is shown that there is an increase in half-life for mature 
proteins while there is an increase in turnover in the intermediate forms [65, 66]. Thus, the roles 
of Oct1 and Icp55 are to stabilize the N-termini of the proteins post-MPP processing, which can 
produce intermediate, unstable N-termini [65, 66]. Figure 3 is a simplified illustration to show 
that MTSs direct proteins from the cytosol to their final destinations. The MTSs are cleaved off 
from the proteins by various proteases to yield the final, mature forms. 
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 Figure 3. MTSs Direct Proteins from the Cytosol to Their Final Destinations. 
Protein 1 passes through the TOM Complex and is laterally translocated to the IMM. 
Different proteases from the matrix and from the inner membrane space cleave off the MTS and 
the transmembrane region to yield a mature protein 1 in the inner membrane space. Protein 2 
passes through the TOM Complex and once the transmembrane domain reaches the TIM 
Complex the protein is laterally translocated to the IMM. Protease from the matrix cleaves the N-
terminal MTS to yield a mature protein 2 localized to the IMM. Protein 3 passes through the 
TIM-TOM Complex and the N-terminal MTS is cleaved to yield a mature protein 3 residing in 
the matrix. OMM is outer mitochondrial membrane. IMM is inner mitochondrial membrane. 
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 1.2.2 Mitochondrial Protein Import Pathways 
It is estimated that there are about 1000 proteins in the mitochondria of yeast Saccharomyces 
cerevisiae [67] and up to 1500 proteins in human mitochondria [68]. However, more than 98% 
of mitochondrial proteins are translated in the cytosol [48]. Mitochondrial proteins translated in 
the cytosol can be trafficked to the matrix, the inner membrane, the inner membrane space, or the 
outer membrane. 
1.2.2.1  Protein Import to Matrix 
Translocase of the outer membrane (TOM) complex and Translocase of the inner membrane 
(TIM) complex are the major components in transporting mitochondrial proteins from the 
cytosol into the matrix. TOM complex is the first component of the mitochondrial protein import 
machinery; virtually all mitochondrial proteins pass through TOM complex [49]. Most of the 
knowledge regarding TOM complex comes from Neurospora crassa and Saccharomyces 
cerevisiae, but the structure and function of the TOM complex in those organisms are 
comparable to those in animals and plants as well [69-71]. TOM complex has a molecular mass 
of 490-600kDa [72, 73], and seven components constitute the TOM complex, with TOM20, 
TOM22, and TOM70 being the surface receptors and TOM5, TOM6, TOM7, and TOM 40 as 
translocation pores [49]. TOM20 and TOM70 recognize protein precursors but have different 
substrate specificity. TOM 20 is the main receptor for protein precursors with N-terminal MTS 
[74], and TOM70 is important for the import of hydrophobic proteins, including those without 
N-terminal MTS [75]. TOM22 is responsible for connecting TOM20 to the translocation pore 
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and maintaining the integrity of the entire TOM complex [76]. It is also involved in recognition 
of protein precursors with TOM20 [77]. TOM40 is the central component of the translocation 
pore [78] with a β-barrel structure and TOM5, TOM6, and TOM7 are the accessory units. These 
accessory structures seem to stabilize the TOM complex, but their functions depend heavily on 
the model system. TOM6 in both Saccharomyces cerevisiae and Neurospora crassa promote 
stable interaction between TOM22 and TOM40 [79], but the loss of TOM7 in Neurospora 
crassa seems to destabilize the TOM complex [80] while in Saccharomyces cerevisiae the 
presence of TOM7 promotes a destabilizing effect [81]. Yeast TOM5 is responsible for 
mediating the insertion of protein precursor into the translocation pore [82] while TOM5 plays a 
minor role in Neurospora crassa [80]. 
 
TIM complex consists of 9 components, with TIM17, TIM21, TIM23 and TIM50 
forming the protein transporting channel and TIM14, TIM16, TIM44, mtHSP70, and Mge1 
being the import motor that transports protein into the matrix space. Of the protein transporting 
channel sector, TIM17, TIM23, and TIM50 are essential but TIM21 is not [83]. The short N-
terminus of TIM17 has conserved negative charges, critical for precursor protein import [49, 84]. 
TIM17 is proposed to be important in gating the TIM23 pore [49, 84]. It is also a suppressor of 
mtDNA instability as overexpression of TIM17 leads to long-term mtDNA stabilization in a 
human cancer cell line that is prone to frequent mtDNA loss after the introduction of a 
mitochondrial missense mutation [85]. TIM21 interacts with the TOM complex by binding to the 
inner membrane space domain of TOM22 [83]. It also recruits complex III and complex IV of 
the respiratory chain and promotes preprotein insertion into the inner membrane [86]. TIM23 is 
the translocation channel [87] and the N-terminus of TIM23 consists of two parts: The first part 
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spanned the outer membrane and might help link TIM23 between the inner and the outer 
membrane [88]. It also facilitates the transfer of precursor protein from TOM to TIM and is 
essential for the survival of yeast at elevated temperature [88]. The second part, which spans 
from residue 50-100, is a coiled-coil domain that is essential for substrate binding and 
dimerization [89]. TIM50 is characterized by having a major domain exposed to the inner 
membrane space, and it is responsible for directing matrix-targeting precursor protein to TIM23 
[90], recognizing precursor proteins that are destined for inner membrane [91], and linking the 
outer and inner mitochondrial membrane [92].  
 
TIM14, TIM16, TIM44, mtHSP70, and Mge1 constitute the import motor. They are 
essential to translocate the rest of the precursor protein as the protein transporting channel sector 
can only transport the MTS of precursor protein with the energy derived from membrane 
potential. TIM14 is a DnaJ protein family member, with an essential J-domain facing the matrix 
and a single transmembrane domain embedding in the inner membrane [93]. It interacts with 
mtHSP70 [94] and TIM44 and such interaction is ATP-dependent [95]. It has been determined 
that TIM14 is required for efficient binding between mtHSP70 and the precursor protein and for 
the release of the mtHSP70-precursor complex from TIM44 [95]. TIM16 is another DnaJ 
homolog and interacts with TIM14 [96] for the formation of mtHSP70-precursor complex [97]. 
TIM16 is required for precursor proteins that are destined to the matrix but dispensable for those 
inserted into the inner mitochondrial membrane [97]. TIM44 interacts with TIM23, one of the 
membrane components of the TIM complex [98, 99]. TIM44 is capable of recruiting ATP-bound 
mtHSP70, which, like other HSP70 chaperones, has an ATPase domain at the N-terminus and a 
precursor protein-binding domain at the C-terminus [100, 101]. When mtHSP70 is bound to 
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ATP, it has an open pocket conformation that allows it to grasp the precursor protein. Once ATP 
is hydrolyzed, the ADP-bound mtHSP70 will develop low affinity for TIM44, and mtHSP70 is 
released from the import site [102]. The precursor protein will be imported into the matrix as 
mtHSP70 prevents it from sliding backwards [103]. Mge1 is essential in promoting the release of 
ADP from mtHSP70 [102]. 
1.2.2.2 Protein Import to Inner Membrane 
Precursor proteins that are destined to the inner membrane utilized the TIM-TOM complex 
similar to the ones that are destined to the matrix. However, additional proteins are required to 
help process and insert them into the inner membrane. Three pathways have been identified: the 
TIM22 Pathway, the Stop-Transfer Pathway, and the Conservative Sorting Pathway. 
The TIM22 pathway 
The TIM22 pathway utilizes the TOM complex, small TIM proteins, and the TIM22 
complex. Precursor proteins pass through the TOM complex and are then escorted by small TIM 
proteins to the TIM22 complex at the inner membrane [104]. Small TIM proteins include TIM9, 
TIM10, and TIM12. TIM9 stabilizes the T9-T10 complex, while the N-terminal of TIM10 serves 
as a substrate sensor and the C-terminal plays an essential role for complex formation [105]. 
TIM12 works downstream of TIM9-TIM10 complex, and it functions as a linker subunit 
between the soluble translocases and the membrane-bound translocases [106]. The TIM22 
complex consists of SDH3, TIM18, TIM22, and TIM54. TIM22 is similar to TIM17 and TIM23 
in sequence [107] and is the only essential protein of this complex, combining the functions of 
energy transduction, signal recognition, and channel formation in one component [108]. SDH3-
TIM18 complex has roles in biogenesis and assembly of the TIM22 complex [109]. TIM54 is 
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involved in scaffolding and stability of the TIM22 complex and the assembly of a proteolytic 
complex, Yme1p [110]. Precursor proteins that utilize the TIM22 pathway include members of 
the solute carrier family and TIM17, TIM22, and TIM23. All of these precursor proteins share 
the characteristics of having even number transmembrane segments with both the N-terminus 
and the C-terminus exposed to the inner membrane space [49]. 
 
Stop-Transfer Pathway 
The Stop-Transfer Pathway utilizes the TOM Complex and TIM23. Precursor proteins 
that utilize the Stop-Transfer Pathway generally have only one transmembrane segment and the 
N-terminus usually stays inside the matrix while the C-terminus stays in the inner membrane 
space [49]. The sorting signal is embedded in the transmembrane domain and it arrests the 
precursor protein during import and inserts the protein to the lipid bilayer laterally, and hence the 
name “stop-transfer”. Deletion of the transmembrane segment will lead to the precursor protein 
being transported into the matrix [111]. The general characteristics of the internal signal for the 
Stop-Transfer Pathway have been elucidated. The transmembrane segment of the precursor 
protein tends to lack proline residues [112], have a strong hydrophobic character [112], and the 
C-termini of the precursor proteins often have clusters of charged amino acids [113]. Proteins 
that appear to utilize the stop-transfer pathway include Cox5a, Cox11, Dld1, Tim50, Yme1, and 
Yme2.  
The Conservative Pathway 
Precursor proteins go through the TIM-TOM Complex and are targeted to the matrix, just 
like the precursor proteins that are destined to be in the matrix. However, these precursor 
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proteins are reinserted back into the inner membrane [49, 114]. Import into the matrix and the 
subsequent reinsertion are two distinct events; the N-terminus of a protein cannot be transported 
out of the matrix if the MTS is not processed [115]. Delta pH is required for the N-terminal 
translocation and matrix ATP hydrolysis is essential for the export of the protein into the inner 
membrane and the release of the mature protein from mtHSP70 [115]. OXA1 is a crucial 
component in inserting not only imported proteins from the cytosol but also nascent proteins 
synthesized inside mitochondria into the inner membrane from the matrix [116, 117]. Proteins 
that utilize the conservative sorting pathway tend to have proline residues in the transmembrane 
domain, lower hydrophobicity score [112], and multiple transmembrane segments [49]. Proteins 
that utilize the conservative sorting pathway include ATP9 from Neurospora crassa [115], Oxa1 
[114], Oxa2 [118], Mrs2, and Yta10 [119]. Figure 4 illustrates the three pathways utilized by 
proteins destined to the inner mitochondrial membrane. 
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 Figure 4. TIM22, Stop-Transfer, and Conservative Pathway for Proteins Destined to 
the Inner Mitochondrial Membrane. 
Proteins that utilize the TIM22 Pathway pass through TOM complex and TIM22 (black). 
This pathway is utilized by solute carrier family proteins. Proteins that utilize the Stop-Transfer 
Pathway usually have a single transmembrane domain (red) and are translocated laterally from 
TIM23 to the IMM. Proteins that utilize the Conservative Pathway usually have multiple 
transmembrane domains (blue). They are translocated to the matrix and are reinserted into the 
IMM by OXA1 protein.  OMM is outer mitochondrial membrane. IMM is inner mitochondrial 
membrane. 
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 1.2.2.3 Protein Import to Inner Membrane Space 
There are three classes of proteins destined to the inner membrane space, depending on their 
import mechanisms. The first class of protein has a two-part presequence - a classical N-terminal 
MTS and a hydrophobic segment. These precursor proteins go through the TOM Complex and 
interact with the TIM23 Complex. Generally, the N-terminus of the precursor protein goes into 
the matrix and the hydrophobic segment is arrested at the inner membrane and translocate 
laterally. The MPP will cleave the N-terminal MTS while the IMP complex in the inner 
membrane space will cleave the transmembrane portion to yield the mature protein [49, 120]. 
However, many different proteases have been identified to mediate cleavage and release of these 
inner membrane space proteins. For example, the yeast protein cytochrome c peroxidase (Ccp1) 
requires the m-AAA protease and a rhomboid peptidase Pcp1 to yield the final, mature Ccp1 
protein [121]. The second class of proteins that are destined to the inner membrane space are 
usually small, and once they pass through the TOM complex they often are bound by an enzyme 
and are folded into stable forms by metal cofactors or disulfide bridges [49]. Apocytochrome c 
(without heme) is transported through the TOM complex [122] into the inner membrane space 
where it is bound by cytochrome c heme lyase [123, 124]. Cytochrome c is formed when heme is 
inserted. Its folded state prevents it from migrating out of the inner membrane space [49]. 
Precursor small TIM proteins interact with inner membrane protein Mia40 and are trapped in the 
inner membrane space by disulfide bridges [125, 126]. Copper-zinc-superoxide dismutase 
(SOD1) requires both metal cofactors and disulfide bridges in the inner membrane space for its 
uptake into the mitochondria [127]. The third class of inner membrane space proteins is 
membrane-bound. A classic example is cytochrome c heme lyase. It is imported without utilizing 
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ATP hydrolysis or electrochemical potential [128]. It is believed that binding to the affinity sites 
in the inner membrane space drives the translocation [49]. 
1.2.2.4 Protein Import to Outer Membrane 
Proteins that are destined to the outer membrane utilize the TOM complex and the translocase of 
outer membrane β-barrel proteins (TOB) complex [129, 130], also known as the sorting and 
assembly machinery (SAM) complex [131]. β-barrel proteins are found only in the chloroplasts 
or the outer membrane of mitochondria in eukaryotic cells [132]. β-barrel proteins have multiple 
membrane-spanning segments that are 9-11 amino acid long [133], and require both TOM 
complex and TOB complex. There are three components to the TOB/SAM complex. TOM50, 
also known as SAM50 or TOB55, consists of two domains. The N-terminus is hydrophilic and 
has a novel structure, polypeptide translocation associated (POTRA) domain. It is involved in the 
release of precursor protein from the TOB/SAM complex [134]. MAS37, also known as SAM37 
or TOM37, and TOB38, also known as SAM35 or TOM38, are the hydrophilic components of 
the TOB/SAM complex that reside on the cytosolic surface [135-137]. Both TOM50 and TOB38 
are essential for yeast survival, but MAS37 is dispensable [137]. MAS37 is, however, essential 
for growth at elevated temperature [138], and it has a genetic interaction with TOM6 [139]. 
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1.3 ATP SYNTHASE OVERVIEW 
1.3.1 Types of ATP Synthase 
There are three types of ATPases: F-type ATPases, also known as F1Fo (o stands for oligomycin-
sensitive) ATPases, V-type ATPases, and A-type ATPases [140, 141]. They are related in 
structures and mechanisms but have different functions and origins. F-type ATPases and V-type 
ATPases exist in eukaryotes, while A-type ATPases exist in archaea [141]. F-type ATPases 
synthesize ATP and hydrolyze ATP by reverse reaction, while V-type ATPases utilizes ATPs to 
pump proton across membranes. They are seen in intracellular membranes to maintain acidified 
compartments or in plasma membranes to pump protons out of cells [142, 143]. V-type ATPases 
are found in osteoclasts [144], epididymal lumen [145], distal nephron [146], renal proximal 
tubules [147], and inner ear [148], A-ATPases, not surprisingly, are structurally simpler [141]. 
Even though all three of the ATPases are related in structures, A-ATPases and V-ATPases are 
evolutionarily closer, with A-ATPases having two peripheral stalks and V-ATPases having three 
peripheral stalks and forming E-G heterodimer [141]. In this dissertation, we will focus solely on 
F-type or F1Fo ATPases. 
1.3.2 Structure and Functions of ATP Synthase 
ATP synthase is an extremely complex structure. Attempts have been made to describe the 
structure using the mitochondria isolated from E. coli, yeast, bovine heart, and human cells. The 
subunit compositions, stoichiometry, and genetic specifications of F1Fo ATP synthases of E. coli, 
yeast, bovine, and human are detailed in Table 1. The X-ray crystallographic structure for the 
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catalytic F1 portion was first partially solved by Walker and his group in 1994 using bovine heart 
mitochondria [149] and more structural details have followed since [150-156]. Human ATP 
synthase, also known as Complex V, utilizes the proton electrochemical gradient to generate 
energy to phosphorylate ADP to ATP. The ATP synthase has two domains: F1 and Fo. F1 is the 
“central stalk” portion that extends into the matrix and has 5 different subunit types (3α, 3β, 1γ, 
1δ, and 1ε) [149, 154]. Fo is the hydrophobic portion that is bound to the inner mitochondrial 
membrane and consists of main subunits a, b, c (8 identical units), d, F6, oligomycin sensitivity-
conferring protein (OSCP) and accessory subunits e, f, g, and A6L [150, 157-159]. When 
protons cross from the intermembrane space to matrix through the inner mitochondrial 
membrane (IMM), a proton gradient is formed to establish a proton-motive force. This energy 
turns the c-subunit ring in Fo and the subunits γ, δ, ε from F1, which sit on top of the c-subunit 
ring. Rotation of γ within the stationary α3β3 hexamer leads to ATP synthesis [160, 161]. A 
stylized model of ATP synthesis is shown in Figure 5. Notably, only the Fo subunits a (ATP6) 
and A6L (ATP8) are encoded by the mtDNA [162]. 
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Table 1. Stochiometry and Subunits of E.coli, Yeast, and Human ATP Synthase. 
t.b.d. is to be determined. Table adapted from Rodenburg, 2012 [163]. 
 Stoichiometry Prokaryotes Eukaryotes 
  E.coli S.cerevisiae H.sapiens 
F1 3 α α α 
 3 β β β 
 1 γ γ γ 
 1 ε δ δ 
 1 - ε ε 
 1 δ OSCP OSCP 
Fo 1 a 6 A 
 1 - 8 A6L 
 10-15 C10-12 910 c8 
 1-2 b2 4 B 
 1 - d D 
 1 - h F6 
 1 - f F 
 t.b.d. - e E 
 t.b.d. - g G 
 1 - i - 
 1 - k - 
Regulators 1 - Inh1p IF1 
 t.b.d. - Stf1p - 
 t.b.d. - Stf2p - 
Total Subunits  22 33 27 
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Figure 5. Model of Escherichia coli ATP Synthase (Complex V).  
Complex V is comprised of F1 and Fo. The a subunit, also known as ATP6 in yeast and 
Drosophila, in the Fo portion will be the focus of this thesis. This diagram is modified from 
Weber J. Biochim Biophys Acta. 2006 Sep-Oct;1757(9-10):1162-70 [164]. 
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 1.3.3 Assembly of ATP Synthase 
ATP synthase contains multiple subunits that require stepwise assembly. In a detailed paper that 
utilizes extensive radioactive labeling in yeast, the c-ring and F1 are formed independently and 
are then assembled [165]. F1 transactivates ATP6 and ATP8, the two mitochondrially-encoded 
proteins, which form into a complex [165]. It is still unclear at what stage the peripheral stalk 
(stator) joins the complex. However, it is consistent with previous reports that ATP6/ATP8 
complex are connected with the rest of the complex at a much later stage [165]. Therefore, the 
assembly is not a single linear process but a parallel, separate and well-coordinated event. In 
human cells, the assembly process is slightly different. It is suggested that, like yeast, the F1 
complex is formed first. The formation of F1 complex directs the formation of subunit c 
complex. F1 complex and subunit c complex attach to each other, and the incorporation of other 
subunits follow [166].  By utilizing doxycycline to halt translation [166], examining the ATP 
synthase structure in patients with ATP6 mutation [167, 168], and decreasing the ATP6 mRNA 
transcripts [169], different researchers have identified intermediate, partially-assembled 
complexes and concurred that the incorporation of ATP6 protein takes place at the late stage of 
assembly.  
 27 
2.0  MITOCHONDRIAL ENCEPHALOMYOPATHIES AND ATP6 MUTATIONS 
2.1 EPIDEMIOLOGY OF MITOCHONDRIAL ENCEPHALOMYOPATHIES 
Mitochondrial Encephalomyopathies (MEs) consist of large groups of syndromes that have an 
overall prevalence of 10 patients with clinically relevant disease per 100,000 in the adult 
population [170] and affect 1 in 5000 newborns [171]. One study, utilizing randomly ascertained 
neonatal-cord-blood samples instead of clinically affected subjects, detects a pathogenic 
mutation in 1/200 live births [172]. There are two classes of MEs: class I MEs directly affect 
mtDNA or nuclear genes that encode OXPHOS proteins [173], and class II MEs involve 
nucleus-encoded mitochondrial proteins that are not OXPHOS-related [174]. ME syndromes are 
typified by characteristic neurological manifestations including seizures, encephalopathy, and 
stroke-like episodes, as well as other frequent secondary manifestations including cognitive 
impairment, migraines, cardiomyopathy, and diabetes mellitus [175]. Currently, there is no 
consensus criterion for treating mitochondrial diseases [176]. There are more than 250 mutations 
in class I ME (http://www.mitomap.org; accessed on July 17 2013) [177], and the most severe 
forms are the ones with mutations in the mtDNA. This is especially true of mutations that affect 
tRNAs and protein-coding genes such as ATP6. ATP6 is a subunit of the mitochondrial F1Fo –
ATP synthase. This enzyme, also known as complex V of the electron transport chain, is 
responsible for the final step of oxidative phosphorylation. 23 mutations have been identified in 
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the ATP6 gene, of which 7 are associated with NARP [178-182], MILS [183-191], and Familial 
Bilateral Striatal Necrosis (FBSN) [192, 193]. Of these 7 mutations, all are missense mutations 
(http://www.mitomap.org; accessed on July 17 2013) [177]. 
2.2 PATHOGENESIS OF ATP6 MUTATIONS 
2.2.1 Heterogeneity of ATP6 Phenotypes 
Patients and models with ATP6 mutations present vastly different phenotypes and pathogeneses. 
ATP6 mutations are usually heteroplasmic and lack tissue- and age-related variations [194], and 
family members with identical T8993G mutations can present with NARP or MILS [195, 196]. 
This is not surprising because the severity of presentation is correlated to mutant load. However, 
oligosymptomatic children can have similar mutant loads as their symptomatic siblings [197], 
and it has been reported that patients with high mutational load of T8993G do not always exhibit 
typical NARP/MILS phenotypes [198]. More interestingly, two point mutations at the same 
nucleotide can have very different pathogenic components [199]. For example, both 8993T>G 
and 8993T>C can lead to energy deprivation and ROS overproduction, but pathogenesis of 
8993T>G (L156R) is caused by energy deficiency and has a more severe phenotype, while 
8993T>C (L156P) leads to ROS overproduction and has a milder phenotype with a slight 
decrease of maximal ATP production [190, 200, 201]. In lymphocytes obtained from patients, a 
20% ATP synthesis decrease is observed in cells with 8993T>C mutation, but a 65% ATP 
synthesis decrease is observed in cells with 8993T>G mutation [199]. A similar phenotypic 
presentation is also observed with point mutation at nucleotide 9176, with a T>G (L217R) 
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mutation being more clinically severe than the T>C mutation (L217P) [183, 184, 193, 202]. It is 
important to note that both mutation pairs occur at the same nucleotide (8993 or 9176) and 
change the same amino acid (Leu to Arg or Leu to Pro). 
2.2.2 Defects in Proton Flow 
It has been suggested that ATP6 pathogenesis is due to a change in formation that impedes 
proton flow and interaction between subunits a and c [37]. A model of how proton passes 
through E.coli ATP synthase has been proposed [203]. Initially, positively-charged Arg-210 on 
subunit a interacts with the deprotonated, negatively charged Asp-61 on subunit c. When proton 
passes through the channel, Asp61 becomes protonated and causes the subunit c to rotate. This 
rotation puts Arg-210 into an altered position and in order to release the strain it snaps forward 
and becomes opposite to the next subunit c. When the proton exits, the next subunit c becomes 
deprotonated so the initial conformation is re-established but with the subunit c having rotated by 
30 degree [203]. It is suggested that mutation of Leu (a highly conserved neutral amino acid) to 
Arg (a basic amino acid) reduces the ATP synthesis efficiency due to inappropriate interactions. 
In the case of Leu to Pro mutation, proline, being a classic helix breaker, distorts the proton 
channel to impede the flow and interferes with A6  c contacts [37]. This hypothesis is 
supported by increased matrix pH (i.e. fewer protons flow through) in T8993G cell cybrids 
[204]. 
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2.2.3 Inefficient Coupling of Proton Transport and ATP Synthesis 
In contrast to the hypothesis that the ATP6 pathogenesis is due to impeded proton flow, it has 
been suggested that the defect in ATP synthesis lies in the inefficient coupling between proton 
transport and ATP synthesis and there is no defect in proton flow [205, 206]. ATP is added to 
submitochondrial particles to allow ATP hydrolysis to occur as proton-pumping activity requires 
ATP hydrolysis. Proton-pumping activity is indicated by acidification of vesicles and measured 
by fluorescence. It has been shown that platelets obtained from patients and those obtained from 
control have essentially the same proton-pumping profiles, suggesting that the reduction of ATP 
synthesis is not due to impeded proton flow [205]. Fluorescent dye Rhodamine-123 is also used 
to determine passive proton flux, but there is no significant difference between cells from 
patients and cells from control [206], reiterating the point that protein flow is intact. 
2.2.4 Defects in Bioenergetics 
Because ATP6 is a subunit of the ATP synthase, changes in bioenergetics have been 
investigated. Cell cybrid systems are used to compare cell lines with different mutations 
(T8993G, T9176G, T8993C) and it is shown that all of them have variable degrees of ATP 
synthesis defects, even though all of them have 100% of the mutations. More surprisingly, 
variations exist among cell lines with the same mutations [207]. Cell lines with severe ATP 
synthesis defects show reduced mitochondrial respiration and reduced Complex I and IV 
activities, suggesting electron transport chain defects. In yeast, a strain without ATP6 has been 
developed [208]. Not surprisingly, neither oligomycin-sensitive ATP synthase activity nor ATP-
driven proton translocation is detected. However, the lack of ATP6 also leads to a substantial 
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decrease in cytochrome c oxidase [208]. It has been shown that bioenergetics is unlikely to be 
the culprit of ATP6 pathogenesis in an in vivo model [209]. Because the ATP6[1] mutants show 
a progressive nature of neurodysfunction, their levels of phosphoarginine (P-Arg), arginine 
(Arg), and adenylate pool (ATP, ADP, and AMP) have been examined at different time points of 
their adult lives. When the ATP6[1] mutants are young and asymptomatic, they have decreased 
P-Arg/Arg ratios and decreased ATP/ADP ratios. However, the P-Arg/Arg ratios and ATP/ADP 
ratios of the ATP6[1] mutants are not different from those of the age-matched controls when the 
mutants become symptomatic [209]. This suggests that bioenergetics changes do not cause age-
related pathogenesis. 
2.2.5 Defects in Assembly 
Other explanations to describe the underlying ATP6 pathogenesis have been sought besides 
defects in bioenergetics. In the T8993G mutation model, the ATP synthesis is drastically reduced 
in both humans [167, 205, 210, 211] and yeast [212] but the ATP synthase assembly and stability 
is not affected [213]. However, this issue is controversial as ATP synthase assembly is impaired 
in T8993G mutation cell line [168]. In T9176G mutation, ATP synthase assembly is significantly 
disrupted in yeast [214]. Subcomplexes of ATP synthase are detected and the few fully 
assembled F1Fo complexes are very fragile and can easily dissociate into subcomplexes during 
detergent extraction [208]. However, the same mutation is shown to have a fully assembled yet 
inactive ATP synthase in Escherichia coli [215]. For T9176C mutation in yeast, the assembly of 
ATP synthase is mostly unaffected but ATP synthesis is decreased by 30-50% [216]. It is 
suggested that the proline residue affects the interaction between the ATP6 protein and the 
subunit c ring [216]. 
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2.2.6 Defects in Membrane Fusion 
A yeast model shows that membrane fusion is inhibited in ATP6 defective cells [217]. Utilizing 
yeast mutants lacking the entire ATP6 gene and mutants having missense mutations leading to 
L183R or L247R alterations (homologous to human T8993G/L156R and human 
T9176G/L217R, respectively), it has been shown that the majority of the zygotes have mixed 
fusion profiles when the mutants are incubated with wildtype (WT) yeast, suggesting that there is 
a dominant inhibition in membrane fusion. Moreover, the defect is in inner membrane fusion 
while the outer membrane fusion remains intact as fluorescent protein attached to mitochondrial 
outer membrane shows similar kinetics to those of the WT [217]. 
2.2.7 Increase in ROS Production 
ROS production has been shown to increase in both in vitro and in vivo models. In lymphocytes 
with 8993TG/C mutation, there are increased ROS production and ROS-neutralizing enzymes 
activities [199]. Measurement of ROS production for this experiment has been made by 5-(and -
6) chloromethyl-2.7-dichlorofluorescein diacetate (CM-DCFDA) fluorescence dye. It is 
noteworthy that a weakness of this dye is that it readily detects hydroxyl radical and 
peroxynitrite but not hydrogen peroxide or superoxide [218]. Mitochondrial Mn-SOD and 
cytosolic CuZn-SOD activities increase drastically in 8993T G cells but not in 8993T C 
cells, and catalase activity is not increased in either cell type [199]. The Palladino lab has 
generated a Drosophila strain that utilizes genetically encoded redox sensors (roGFPs) to 
monitor mitochondrial redox changes [219]. This probe is advantageous to exogenous probes 
because real-time detection of redox status in live cells is possible and the need to permeate and 
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incubate tissues with dye is minimized. They have shown that there is a progressive, age-related 
increase in redox change in ATP6[1] mutants comparing to age-matched controls and that no 
dysfunction is detectable in young mutants. Moreover, treatment with mitochondrial-targeted 
antioxidants improves the lifespan of ATP6[1] mutants and reduces mitochondrial oxidative 
stress in those animals [219]. 
 
2.2.8 The Effects of Inflammation on the Pathogenesis of ATP6 Mutation 
The role of inflammation in seizures has increasingly been recognized. However, seizure 
pathogenesis resulting from chronic mitochondrial dysfunction is not understood. Mutations in 
mtDNA that affect oxidative phosphorylation can lead to increased reactive oxygen species 
(ROS) production [220, 221]. Previous data from our lab has shown that mitochondrial reactive 
oxygen species (mtROS) is highly elevated in our ATP6[1] flies [219]. Studies have shown that 
mtROS can lead to the release of proinflammatory cytokines in mouse models and human cells 
in vitro [222-225]. Treatment with SOD mimetics, a reactive oxygen species (ROS) scavenger, 
inhibits proinflammatory cytokine production [226-228], suggesting that elevated ROS likely 
leads to inflammation activation. Furthermore, applying proinflammatory molecules, such as 
Interleukin (IL)-1β and Tumor Necrosis Factor (TNF)-α, to the brain exacerbated or provoked 
seizure activity, the mechanism of which is not known [229, 230]. Inflammation is defined as a 
homeostatic phenomenon induced by various types of properties by cells of the immune system, 
including both innate and adaptive immunity cell types [231]. Previously, it is shown that 
blockage of IL-1β and TNF-α [230, 232, 233], and Toll-like receptor signaling pathways [234] 
mediates powerful anti-convulsant effects. Moreover, in human febrile seizures, seizures 
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commence after inflammation (usually due to infections), so it is well established that 
inflammation can lead to seizure. A case report has also shown that febrile illness can exacerbate 
the symptoms of mitochondrial disease [235]. However, experimental evidence also suggests 
that inducing seizures in rats and mice can lead to the release of inflammatory mediators [236-
239]. Therefore, in our aseptic fly model with a “built-in” seizure propensity, whether 
inflammation takes place and what effect it imposes on the seizure phenotype remain to be 
determined. 
2.3 MODEL SYSTEMS TO STUDY ATP6 MUTATIONS 
2.3.1 Escherichia coli 
Multiple E.coli models have been developed to model human ATP mutations. A T8993G 
mutation [240] and a T8993C mutation [241] have been constructed in E.coli. The E. coli model 
with a T8993G mutation fails to grow, suggesting that the mutation causes a substantial loss in 
oxidative phosphorylation. A follow-up fluorescence quenching experiment shows that the 
mutation leads to inhibition of proton translocation [240], suggesting that E.coli is very sensitive 
to the Leu  Arg change as this leads to a complete loss of ATP synthesis and proton pumping 
activities. The same group has also developed a E.coli strain with T8993C mutation, and the 
strain with a T8993C mutation has about 60% intact Fo subunit while the one with a T8993G 
mutation has less than 40% [241]. Strain that has T8993C mutation had about 30% of proton 
pumping capacity and close to 10% passive protein translocation upon F1 depletion comparing to 
WT, which are both less severe than the T8993G phenotype. This is similar to what has been 
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observed in another model system cybrid. However, while the assembly of L156R ATP6 into the 
human ATP synthase complex is not affected [211, 213], the mutant L207R subunit a (the 
equivalent of L156R ATP6 in humans) cannot be inserted into the bacterial synthase complex 
[215]. Moreover, bacterial ATP synthase is missing at least 10 subunits that are present in the 
human ATP synthase [242]. For these reasons, other more suitable, eukaryotic models are sought 
after. 
2.3.2 Yeast 
Multiple Saccharomyces cerevisiae models with ATP6 mutations have been developed and 
characterized [212, 214, 216, 243]. Yeast with NARP T8993G mutation grow very slowly 
possibly because the ATP synthesis rate is only 10% comparing to that of WT, although the ATP 
synthase is correctly assembled and is present at 80% WT level [212]. Unlike human NARP cells 
[37, 205], ATP hydrolysis in intact yeast mitochondria is significantly compromised. The oxygen 
consumption rate is also significantly lowered by 80% due to a decrease in the cytochrome c 
oxidase (complex IV) content [212]. Yeast with T8993C mutation has a 40-50% ATP synthesis 
rate comparing to that of WT, and although there is neither a deficit in ATP6 protein synthesis 
nor a deficit in proton translocation, the assembly of ATP6 into the ATP synthase complex is 
very unstable [243]. In yeast with 9176G mutation, the ATP synthesis rate is drastically reduced 
by >95%. The ATP6 protein is synthesized but incorporation of the ATP6 protein into the ATP 
synthase complex is not efficient [214]. In yeast with 9176C mutation, there is a 30% reduction 
in ATP production. However, a number of sub-complexes are detected, suggesting the decreased 
stability of ATP6 protein within the ATP synthase complex [216]. 
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2.3.3 The Cybrid System 
Cybrid, also known as transmitochondrial hybrid, is the fusion of an enucleated cell with mutant 
mtDNA and a mitochondrial-less cell (ρ° cell), usually from the immortal cell lines [244]. The 
protocol involves the fusion of platelets with mutant mtDNA and osteosarcoma cells with no 
mtDNA [210, 245]. Cybrid cell lines with different levels of mutant mtDNA can be made. The 
advantage of the cell cybrid system is that it allows comparisons among different individuals as 
the nuclear confounding variables are eliminated. However, there are many drawbacks to this 
approach. Cybrids can exhibit high degree of variability in pathogenesis and wide variations in 
biochemical defects among cell lines with the same mutations (see section 2.2.4) [207]. Cybrids 
are also fusion cells that do not resemble cells in the natural state, and the nuclear background of 
the ρ° cells will affect the heteroplasmic stability of the mtDNA [246, 247], the biochemical 
defects of the complexes [248], and the phenotypes [249, 250] of the models. The physiology of 
the mitochondria isolated from different tissues to make cybrids can be drastically different 
[251], and the nuclear DNA determines mitochondrial functions depending on the specific 
tissues [252]. The cybrid system requires a much higher mutation load than that seen in humans 
to alter biochemical parameters, suggesting that this approach may not reflect the human disease 
processes [253]. Also, the growth of cybrids is highly subjected to the medium conditions (e.g. 
galatose vs. glucose) [210] and may not reflect the complex metabolic demands in intact tissues. 
The ρ° cells are derived from tumor cells, of which often have chromosomal rearrangements. 
Because only 2 subunits of the ATP synthase complex are mitochondrially encoded and the rest 
are encoded in the nucleus, the abnormal chromosomal number/arrangement or altered nuclear-
mitochondrial interactions may affect the stoichiometry of the complex (i.e. excessive or 
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depleted numbers of certain subunits), complicating the analysis of mitochondrial genotype-
phenotype correlation [254]. Lastly, tumor cell lines are generally glycolysis dependent, which 
may not mirror myopathies that usually occur in more aerobic cells. 
 
Besides being used to study pathogenesis, cellular cybrids and various mutant cell lines 
have also been widely used to determine the efficacies of a gene therapy approach known as 
allotopic expression. Allotopic expression involves expressing a gene that is normally encoded in 
the mitochondria in the nucleus and transporting the protein from the cytosol into mitochondria. 
Allotopic protein import has been examined not only for ATP6 [255-258] but also for ND4 [259-
261], ND6 [262], COX3 [257], cytochrome b [261], and ATP8 [261]. However, the outcomes 
are controversial. ATP8 protein but not ND4 or cytochrome b has been shown to colocalize with 
mitotracker in mitochondria [261], and ND6 has been shown to colocalize to the mitochondria 
but it is incorrectly targeted to the outer mitochondrial membrane [262] (also see. Section 3.1 for 
ATP6-specific outcomes). 
2.3.4 ATP6 Mutant Mice 
Pinkert and his group reported the first transgenic mouse model for ATP6 allotopic expression 
[263]. It is shown that cytoplasmically-translated ATP6 proteins can be localized to 
mitochondria. However, it is doubtful if it would make a good model for ATP6 mitochondrial 
encephalomyopathy. The A6M mice (mice that express mutant ATP6 gene in the nucleus) 
actually performed better in rota-rod test than the control, which did not reflect mitochondrial 
encephalomyopathy phenotype progression as seen in human patients. Moreover, there is no 
significant difference in mitochondrial function between the transgenic mice and the controls. 
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More importantly, the idea of expressing an exogenous mutant ATP6 gene in the nucleus to 
model a disease that had its origin/ mutation in the mitochondria could be problematic. Any 
phenotype that is observed in the mice cannot be conclusively attributed to the ATP6 mutation; 
in fact, it can be due to various factors such as mutant protein accumulation in the cytosol at a 
toxic level. 
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3.0  GENE THERAPY APPROACHES TO MITOCHONDRIAL 
ENCEPHALOMYOPATHIES 
ATP6 synthase subunit a, also known as ATP6 in Drosophila melanogaster and in 
Saccharomyces cerevisiae (yeast), is encoded by the mtDNA ATP6 gene [162]. Several 
approaches to mitochondrial gene therapies have been proposed. Because the presence and 
severity of clinical symptoms depend on the percentage of heteroplasmy, inhibiting the 
replication of mutant mtDNA by antisense oligonucleotides may allow WT mtDNA in the same 
cell to accumulate [264]. However, this might promote mtDNA depletion, where mitochondria 
with deletions in their mtDNA are created [265]. A similar idea of decreasing the ratio of mutant 
mtDNA to WT mtDNA but utilizing a drastically different method has been described recently 
[266]. Mitochondrially-targeted transcription activator-like effector nucleases (mitoTALENs), 
enzymes that enter mitochondria to bind specific sequences of interest, are utilized to 
differentially cleave the mutant mtDNA harboring a ND6 point mutation while sparing the WT 
mtDNA, successfully skewing the mutant mtDNA to WT mtDNA ratio [266]. Another approach 
involves importing WT DNA directly into the mitochondria. However, it is unclear if the very 
different transcription and translation systems of mitochondria, which specialize in handling 
circular DNA molecules, will be able to recognize exogenous DNA, which presumably have a 
very different structure [265]. The approach that is utilized in my dissertation involves 
expressing desired mitochondrial gene in the nucleus (allotopic expression), translating the 
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protein in the cytosol, and importing the protein back into mitochondria. The advantages of this 
approach are that the vast majority of mitochondrial proteins are indeed translated in the cytosol 
and subsequently imported into the mitochondria, and the protein import mechanism by 
translocases of the inner and outer membrane (TIM-TOM complex) is fairly well characterized. 
Such approach has already been successful in yeast. In 1988, Nagley and his group successfully 
rescued an ATP8 mutation phenotypically [267]. However, such approach has yet to be shown 
successful in any animal model and some allotopic expression results remain very controversial. 
Another distinct advantage of this approach is that even inefficient allotopic gene therapy might 
be efficacious to many affected individuals due to the mitochondrial threshold effect. Therefore, 
we rigorously test allotopic expression in vivo and explore the challenges and limitations to this 
approach, as well as design strategies for possible solutions and improvements in efficacy. 
3.1 ALLOTOPIC EXPRESSION OF ATP6 
Because ATP6 is expressed in mitochondria and currently there is no way to introduce foreign 
genes into the mitochondrial genome in higher eukaryotic cells [261], allotopic expression, 
which involves expressing a mtDNA-encoded ATP6 in the nucleus and transporting the ATP6 
protein from the cytosol into the mitochondria, has been suggested as a viable therapy possibility 
[268]. It has been demonstrated successfully in yeast [267, 269]; however, the results from 
mammalian cells are mixed. NARP cybrids expressing oligomycin-resistant ATP6 gene in the 
nucleus can tolerate 1000 folds higher concentration of oligomycin (1000ng/mL vs. 1ng/mL), 
suggesting that the nucleus-encoded oligomycin-resistant ATP6 protein has incorporated into the 
mitochondrial ATP synthase complex [258]. Allotopic expression of ATP6 [255] and 
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specifically algal Chlamydomonas reinhardtii ATP6 [256] have been successful in rescuing a 
human cell line with an ATP6 mutation. However, the result is controversial as it has also been 
shown by another group that the algal protein does not incorporate successfully into Complex V 
[270]. This concern is echoed by a group that utilized mass spectrometry and failed to detect 
algal ATP6 incorporation into the ATP synthase [257]. 
 
3.2 THE ATP6[1] DROSOPHILA MUTANT MODEL 
The Palladino lab has isolated a Drosophila strain with a missense glycine to glutamate mutation 
at position 116 in the ATP6 gene [271]. This fly strain, ATP6[1], exhibits phenotypes that 
include reduced longevity, progressive locomotor impairment, seizures, and neural dysfunction, 
which are very similar to the human disease progression [271]. More specifically, seizures can be 
induced in aged ATP6[1] flies by strobe light, suggesting that sensory hyperstimulation is 
sufficient to induce this specific behavioral phenotype in an age-dependent manner [209], and it 
is documented that strobe light (photostimulation) can induce seizures in susceptible humans 
[272]. This further highlights the suitability of using the ATP6[1] Drosophila as a model for 
mitochondrial encephalomyopathy. Notably, this ATP6[1] mutant model has a 98% ATP6[1] 
heteroplasmy, which is higher than any other heteroplasmy documented in viable organisms. 
Thus, this model provides a rigorous test of efficacy of various allotopic expression strategies 
and takes full advantage of this model’s tractable genetics.  However, this also leads to serious 
challenges in demonstrating rescue effects through functional assays (see discussion). 
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3.3 ENGINEERED ATP6 GENE 
Because mitochondrial codons and nuclear codons are different, recoding is necessary so that the 
correct amino acid sequences will be translated [255]. There are three basic elements to the 
engineered ATP6 in the nucleus: MTS, ATP6 gene, and 3’UTR. A number of transgenic strains 
has been generated and tested by combining different MTSs, recoded ATP6 gene, and 3’UTRs to 
determine the optimal components of an allotopic construct used in vivo (Figure 6).  
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 Figure 6. Allotopic Gene Therapy.  
(A) Basic construct of a nucleus-encoded ATP6 gene. The first part is a mitochondrial 
targeting sequence (MTS), which directs the protein into the mitochondria. The second part is the 
recoded ATP6 gene. Recoding is necessary for proper translation in the nucleus. The third part is 
the 3’ untranslated region (3’UTR). (B) Nucleus-encoded ATP6 gene is transcribed into mRNA 
in the nucleus and translated into protein in the cytosol and import into the mitochondria. 
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 3.4 UAS-GAL4 SYSTEM 
The bipartite UAS/GAL4 system is the most widely used method in Drosophila to achieve 
spatially- controlled gene expression. GAL4 is a yeast transcription activator protein, and 
upstream activating sequences (UAS) is followed by a target transgene cloned downstream. The 
GAL4 strain and the UAS strain are different parental lines combined in the F1 to activate the 
system. Transcription of GAL4 is controlled by promoters with characterized temporal spatial 
patterns. Selected offspring of the mating between the GAL4 and UAS strains will have the 
target gene expressed at specific locations determined by the promoter of GAL4 (Figure 7). 
There are 35717 transgenic GAL4 constructs and 67168 transgenic UAS constructs (Flybase.org, 
accessed on January 13 2014), allowing tremendous combinations. However, there are some 
limitations to the UAS-GAL4 system. For example, it is generally not simple to induce gene 
expression, and systems utilizing ligand-induced GAL4 chimeras have been developed to 
remediate this deficiency. Another potential issue is that many GAL4 lines have dynamic 
expression, so the transcription level of target gene may vary throughout the lifespan of the 
animals. In our studies we have focused on utilizing the daughterless-GAL4 and ubiquitous-
GAL4, both broadly expressed in all tissues, to determine which transgenic combination 
provides the best rescue outcome. 
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Figure 7. The UAS-GAL4 System  
Virgin ATP6[1]; daughterless-GAL4/ daughterless-GAL4 females are mated to male flies 
with the desired transgene (UAS-TG). Female offspring have the maternally inherited ATP6[1] 
as well as one copy each of the UAS-TG and the daughterless-GAL4 and are used in functional 
assays. This figure is modified from St Johnston D. Nat Rev Genet. 2002 Mar; 3(3):176-88 
[273]. 
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 3.5 SITE-SPECIFIC RECOMBINATIONS 
Transgenesis utilizing standard P element-mediated transgeneis often encounters position effects 
as identical transgenes are inserted randomly into the genome. To avoid this issue, we utilized 
pUASTattB transgenesis using the PhiC31-mediated integrase. This allows site-specific 
integration into well-characterized target sites. This specific construct not only is highly efficient 
with 5-10% of the injected embryos producing transgenic animals that are targeted correctly but 
also eliminates the need to analyze multiple versions of each transgene as all transgenes and 
controls are inserted into the same location of the genome. 
3.6  MAJOR HURDLES WITH ALLOTOPIC EXPRESSION 
There are several major hurdles associated with allotopic expression. Hydrophobicity of the 
ATP6 protein and competition for incorporation into the ATP synthase complex between 
exogenous ATP6 and endogenous mutant ATP6 are two major challenges. Additionally, 
avoiding cytoplasmic aggregation, efficient import into a sufficient number of mitochondria, 
proper folding and localization of ATP6 within complex V are also necessary for allotopic 
expression of ATP6 to be an efficacious strategy. We have focused on tackling these two major 
challenges and strategies to overcome these obstacles, which have been detailed below. 
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3.6.1 Hydrophobicity 
The mitochondrial genome has been shedding its genome since its primordial endosymbiont 
ancestor invaded the eukaryotic cell more than a billion years ago, and the gene content of 
mitochondria became stabilized about 800 million years ago [274]. The human mitochondrial 
genome now has a size of 16.5kb and contains 37 genes, of which 13 are protein-coding genes, 
22 are transfer RNAs (tRNAs), and 2 are ribosomal RNAs [162]. Of the 13 protein coding genes, 
7 code for subunits in complex I, 1 in complex III, 3 in complex IV, and 2 in complex V, with 
ATP6 being 1 of the 2 proteins in complex V (the other being ATP8). The fact that these 13 
genes remain in the mitochondrial genome while most of the other genes have transferred to the 
nucleus suggests selective barriers preventing their migration. Several hypotheses have been 
postulated to explain the retention of a mitochondrial genome. It is possible that the nuclear 
genetic code and the mitochondrial genetic code have diverged enough that translating 
mitochondrially-encoded genes by cytoplasmic machinery has become infeasible [275, 276]. It is 
also possible that the 13 protein-coding genes are retained in mitochondria to ensure that the 
assembly of oxidative phosphorylation complex occurs in the inner membrane and prevent 
mistaken insertion of those proteins into other membranes that can lead to cellular damage 
through ROS production [277, 278]. However, it is certain that the polypeptides translated from 
these 13 genes are extremely hydrophobic and will be challenging to transport them from the 
cytosol into the mitochondria. Due to their hydrophobicity, it is likely that the proteins would 
aggregate in the cytoplasm and be degraded by the proteasome or authophagy. Thus, strategies 
that will allow the ATP6 protein to become more hydrophilic and soluble could be critical for 
efficient import.  
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3.6.1.1 Strategy 1: Chlamydomonas reinhardtii ATP6 Subunit 
In eukaryotic organisms, all F1 subunits and most Fo subunits are nucleus-encoded. In yeast, the 
exceptions of the Fo sector are atp6, atp8, and atp9 [279]. These genes encode proteins that are 
highly hydrophobic, with five putative transmembrane regions for ATP6 [279]. However, it has 
been determined that genes that are usually present in the mitochondrial genome in most 
organisms, including nad3, nad4L, cox2, cox3, atp6, atp8, and atp9, are lacking in the 
mitochondrial genomes of some algae, such as Chlamydomonas reinhardtii [280, 281], 
Chlamydomonas eugametos [282], and Chlorogonium elongatum [283]. A study has shown that 
1) calculating the highest average hydrophobicity of 60-80 amino acids in a protein and 2) 
measuring the maximum hydrophobicity of the transmembrane segments provide useful 
indication of the probability that a protein can be imported into mitochondria [284]. By 
establishing that ATP6 protein has 5 transmembrane regions after taking consideration of the 
conserved and essential amino acids and the topology of amino and carboxyl termini, Gonzalez-
Haplhen and his group have quantified the mean hydrophobicity values of ATP6 for 
Chlamydomonas reinhardtii and other plant and algal groups. The three transmembrane 
segments that are presumably not directly involved in proton translocation or interaction with c-
ring subunits have the biggest drop (>50%) in their local hydrophobicity values [279]. This 
might be one of the reasons why the algae Chlamydomonas reinhardtii are one of the few known 
organisms that are capable of expressing ATP6 in the nucleus and transporting the polypeptides 
into the mitochondria. In fact, when we aligned the amino acid sequences of Chlamydomonas 
reinhardtii, Drosophila melanogaster, and human, it was obvious that algae had a very long and 
hydrophilic MTS (Figure 8). We hypothesized that this property was responsible for the 
importability of algal ATP6. In this project, we expressed Chlamydomonas reinhardtii ATP6 
 49 
gene from the nucleus of Drosophila allowing algal ATP6 protein import into Drosophila 
mitochondria. Three transgenic strains have been generated: NoCrAV, NoCrAS and NoCrAO, in 
which No stands for the lack of exogenous MTS, CrA stands for Chlamydomonas reinhardtii 
ATP6, V stands for SV40 3’UTR, S stands for SOD2 3’UTR, and O stands for OXA1 3’UTR. 
Because the algal MTS had its own N-terminal MTS, we thought it was unnecessary to add an 
exogenous MTS to target it to the mitochondria. Three different 3’UTRs were attached to each 
individual strain to determine if it would further improve import (see strategy 3). A potential 
complication associated with this strategy is that the ATP synthase complex may not be 
functional as not all the subunits are derived from the same species. Other groups have attempted 
similar approaches in vitro but the results have been controversial, with one group showing that 
ATP synthase activity is significant improved upon algal allotopic expression [256] and another 
group reports that the algal ATP6 subunit is not assembled into the ATP synthase complex [270]. 
The mating scheme of transgenic strains used is shown in Figure 9. 
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 Figure 8. ATP6 Protein of Chlamydomonas reinhardtii.  
(A) Amino acid alignment of ATP6 polypeptides of Homo sapiens, Mus musculus, 
Drosophila melanogaster, Aedes aegypti, and Chlamydomonas reinhardtii using the Clustal W 
method. The first 100 amino acids of the N-terminus of the algae were removed due to its 
extended mitochondrial targeting sequence for better alignment of the actual ATP6 protein. (B) 
The hydrophobic plots of algal ATP6, Drosophila ATP6, and human ATP6. Algal ATP6 has a 
significantly longer MTS and is more hydrophilic than Drosophila ATP6 and human ATP6.  
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 Figure 9. Generation of Transgenic Fly Strain with the Expression of Nucleus-
Encoded ATP6 transgene (UAS-TG). 
Virgin ATP6[1] flies homozygous for sesB[1] and daughterless-Gal4 (daGal4) were 
maintained as a stable stock.  They were mated to male flies carrying the transgenic nucleus-
encoded ATP6 gene. Because mitochondria are maternally inherited, all the offspring will carry 
the ATP6[1] mutation. However, only the female offspring are used in functional assays to avoid 
behavioral and physiological differences. mt is mitochondria. 
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3.6.1.2 Strategy 2: Mitochondrial Targeting Sequence (MTS) 
Because the Drosophila ATP6 gene is naturally encoded in mitochondria and the protein is 
localized in the inner mitochondrial membrane, it does not normally rely on an MTS to direct it 
into the mitochondria. We have to predict which pathway it would utilize if ATP6 were a 
nucleus-encoded gene and ATP6 protein would require translation and import from the cytosol 
into mitochondria. We have identified a number of MTSs that utilizes different import pathways 
to transport proteins into mitochondria. TIM22, stop-transfer, and conservative pathways are the 
three known pathways that transport proteins into the inner membrane. Of the three pathways, 
stop-transfer and conservative pathways are more likely to be used by Chlamydomonas 
reinhardtii ATP6 because it has an N-terminal MTS [279]. TIM22 is typically utilized by 
membrane-bound TIM subunits and by solute carrier family, such as ADP/ATP carrier proteins 
[49]. One important characteristic of the ADP/ATP carrier proteins is that they typically do not 
have N-terminal MTS [285], Algal ATP6, however, is predicted to have a 107 amino-acid N-
terminal MTS [279], making the TIM22 pathway a less likely candidate to be utilized by both 
algal ATP6 and our engineered fly ATP6 protein. Proteins that utilize the stop-transfer pathway 
tend to have a single transmembrane domain while those that utilize the conservative pathway 
tend to have multiple transmembrane domains. Algal ATP6 is predicted to have five 
transmembrane domains, thus, the conservative pathway is most likely to be used by both the 
algal ATP6 and ATP6 engineered for allotopic expression. The MTSs used in our experiments 
include P1 MTS [255, 286], OXA1 MTS [287], SOD2 MTS [288, 289], DLD MTS [113], and 
COX8 MTS [255, 290]. Their accession numbers and sequences used are listed in Table 2. 
Transgene with no exogenous MTS were also tested. Transgenic strains with one of three 3’ 
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UTRs (see strategy 3) were also used with the MTSs to determine the best functional 
combination.  
Table 2. Mitochondrial Targeting Sequences (MTSs) 
 
The parentheses in the first column indicate the origins of the MTSs. The accession 
number of each MTS and the numbers in the parentheses indicate the start and end nucleotides. 
P1 MTS is originated from humans but has been recoded for optimal expression in Drosophila. 
 
MTS Accession Number Recoded? 
P1 (human) AK311848.1 (34-216) Yes (for fly expression) 
sOxa1 (yeast) BK006939.2 (475020-475080) No 
Sod2 (human) AK313082.1 (1-216) No 
Dld (yeast) NM_001180234.1 (1-216) No 
Cox8 CU687634.1 (17-90) No 
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 3.6.1.3 Strategy 3: SOD2 3’UTR and OXA1 3’UTR 
The vast majority of mitochondrial proteins are encoded in the nucleus and translated in the 
cytosol; therefore, protein transportation from the site of synthesis mitochondria and import are 
critically important for normal mitochondrial function. Considering that protein transport can 
take longer than the protein’s half-life in some cases [291], mRNA localization is a relevant 
factor for ensuring that proteins are translated near the site of import [292]. In fact, more than 
70% of the mRNA present in Drosophila embryos are found in spatially distinct patterns [293], 
suggesting that mRNA localization is a widely adopted strategy for the majority of eukaryotic 
transcripts [294]. 47% of yeast mRNAs encoding mitochondrial proteins are transported to the 
mitochondrial surface [295]. When one of those proteins, ATP2, which encodes the beta subunit 
of ATP synthase, loses its 3’UTR, a severe respiratory deficiency associated with inefficient 
import of the precursor protein is observed, suggesting the importance of 3’UTR in targeting the 
polypeptides to the mitochondrial surface and facilitating the import process [296]. These and 
other findings suggest the likelihood of co-translational mitochondrial import. In HELA cells 
with nucleus-encoded ATP6, more recoded ATP6 RNAs are isolated from the mitochondrion-
bound polysomes in vitro when SOD2 3’UTR is attached to the recoded ATP6 gene in the 
nucleus [288]. Moreover, the recoded ATP6 and endogenous ATP alpha show significant 
colocalization, suggesting that the nucleus-encoded ATP6 protein is translocated into the 
mitochondria. This is further confirmed as a significant amount of the mature form ATP6 protein 
is resistant to protease K digestion and Triton X-100, suggesting that the recoded ATP6, which 
normally resides in the transmembrane region, has been assembled into complex V [288]. 
Attaching a SOD2 3’UTR to ATP6 and ND4 significantly improved fibroblasts’ ability to grow 
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in galactose, which forces the cells to utilize OXPHOS to produce ATP. The growth rates are 
significant higher in the NARP fibroblasts that have both SOD2 MTS and SOD2 3’UTR than 
those with SOD2 MTS and SV40 3’UTR, suggesting that SOD2 3’UTR by itself can significant 
improve functional outcome (cell growth rate). There is also a significant increase in complex V 
activity in NARP flbroblasts with the allotopic expression of ATP6 [289]. We will examine these 
3’UTRs that reportedly allow co-translational import in an in vivo setting. The 3’UTRs and the 
accession numbers are listed in Table 3. The transgenic fly strains generated to test strategies 2 
and 3 are listed in Table 4. 
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 Table 3. 3' Untranslated Region (3'UTR) 
 
The parentheses in the first column indicate the origins of the 3’UTRs. The accession 
number of each 3’UTR is shown in the second column. The numbers in the parentheses in the 
second column indicate the start and end nucleotides.  
 
3’UTR Accession Number Recoded? 
SV40 EF362409.1 (5286-5985) No 
Sod2 (fly) NM_057577.3 (802-862) No 
Oxa1 (yeast) BK006939.2 (475992-476228) No 
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 Table 4. Codes of Transgenic Fly strains for Strategy 2 (MTS) and Strategy 3 
(3'UTR) 
The code is an abbreviation for the MTS, the ATP6 gene, and the 3’UTR used in each 
construct.. The parentheses indicate the origins of the MTS and the 3’UTR.  The ATP6 gene is 
recoded to optimize translation in cytosol following nuclear transcription. 
Code MTS Gene 3’UTR 
PAV P1 (human) recoded fly ATP6 SV40 
sOAV sOxa1 (yeast) recoded fly ATP6 SV40 
SAV Sod2 (human) recoded fly ATP6 SV40 
DAV Dld (yeast) recoded fly ATP6 SV40 
8AV Cox8 recoded fly ATP6 SV40 
noAV No MTS recoded fly ATP6 SV40 
PAS P1 (human) recoded fly ATP6 Sod2 (fly) 
sOAS sOxa1 (yeast) recoded fly ATP6 Sod2 (fly) 
SAS Sod2 (human) recoded fly ATP6 Sod2 (fly) 
DAS Dld (yeast) recoded fly ATP6 Sod2 (fly) 
8AS Cox8 recoded fly ATP6 Sod2 (fly) 
noAS No MTS recoded fly ATP6 Sod2 (fly) 
PAO P1 (human) recoded fly ATP6 Oxa1 (yeast) 
sOAO sOxa1 (yeast) recoded fly ATP6 Oxa1 (yeast) 
SAO Sod2 (human) recoded fly ATP6 Oxa1 (yeast) 
DAO Dld (yeast) recoded fly ATP6 Oxa1 (yeast) 
8AO Cox8 recoded fly ATP6 Oxa1 (yeast) 
noAO No MTS recoded fly ATP6 Oxa1 (yeast) 
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 3.6.1.4 Strategy 4: Suboptimally-Encoded Codons 
Protein transport into mitochondria has been studied for more than three decades [297-300] with 
a strong interest in whether post-translational or co-translational mechanism are used [301]. 
Tagging a mitochondrial targeting sequence (MTS) to a nonmitochondrial protein and adding it 
to purified and isolated mitochondria leads to efficient import of the nonmitochondrial protein 
[302], suggesting a post-translational mechanism. However, several lines of evidence suggests 
that co-translational mechanism is plausible as well. When cyclohexamide is added to yeast 
culture to arrest translation, a large number of ribosomes are found attached to the mitochondrial 
surface [297]. Once the mitochondrion-bound ribosomes are isolated, they are found to have 
more mRNAs for mitochondrial proteins attached to them than the free cytosolic ribosomes 
[303]. Further research shows that ribosomes bind at specific sites on mitochondria [300], and 
strongly suggests that ribosomes binds specifically at protein import sites [304, 305]. Therefore, 
it is possible that co-translational import and post-translational import mechanisms are used for 
different proteins. In fact, co-translational import and post-translational mechanisms might be 
used by the same protein [306]. According to this model, during the early phase translation has 
already been commenced on ribosomes and by the time the ribosomes reach the TOM complex 
the precursor protein translation is completed and the import process is assisted by a molecular 
chaperone. However, during the late phase when the ribosomes have already docked at the TOM 
complex the process switches to co-translational import [306]. If the algal ATP6 and the 
engineered ATP6 utilize co-translational import, a potential complication arises as translation is 
believed to be much more efficient than import [307], utilizing suboptimally-encoded codons 
may slow down translation and allow better synchronization of translation and import. The 
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sequence alignments of the recoded ATP6 and suboptimally-recoded ATP6 are shown in Figure 
10.  We have designed a number of transgenes to test this strategy (Table 5). 
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 Figure 10.  Nucleotide Sequence Alignments of Suboptimally-Encoded ATP6 and 
Recoded ATP6.  
The nucleotides that matched were shown in red. Notice that the amino acid translations 
for both sequences are identical. 
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 Table 5. Codes of Transgenic Fly Strains for Strategy 4 (Suboptimally-Encoded 
Codons). 
s.o.-recoded is suboptimally-encoded. 
 
Code MTS Gene 3’UTR 
SsoAS SOD2 (human) s.o.-recoded ATP6 SOD2 (fly) 
NosoAS No MTS s.o.-recoded ATP6 SOD2 (fly) 
DsoAS DLD (yeast) s.o.-recoded ATP6 SOD2 (fly) 
SsoAO SOD2 (human) s.o.-recoded ATP6 OXA1 (yeast) 
DsoAO DLD (yeast) s.o.-recoded ATP6 OXA1 (yeast) 
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 3.6.1.5 Strategy 5: Mitochondrial Biogenesis Factors –PGC1-α, AMPK, and DSP1 
Peroxisome proliferator-activated receptor (PGC1-α) was the first mitochondria biogenesis 
regulator to be discovered [308]. Cells overexpressing PGC1-α have increased expression of 
Cox II, Cox IV, ATP Synthase, and increased mtDNA content [308]. AMP-activated protein 
kinase (AMPK) plays a major role in mitochondrial biogenesis in chronic energy depletion [309, 
310]. Rats fed with β-guuandinopropionic acid, a pharmacological AMPK activator, for 8 weeks 
have shown increased cytochrome c protein expression and mitochondrial content, suggesting 
that AMPK is involved in mitochondrial biogenesis [311]. Data argue that AMPK works 
upstream of PGC1-α and activates PGC1-α through direct phosphorylation [312]. AMPK also 
phosphorylates ULK1, a human ATG1 homolog, which is responsible for mitophagy [313] (see 
strategy 7). Therefore, AMPK controls mitochondrial homeostasis by increasing the production 
of new mitochondria and removing the old and defective mitochondria [314] The hypothesis for 
this strategy is that overexpressing AMPK or PGC1-α will increase the total number of 
mitochondria, which may help overcome the energy deficits caused by the ATP6 mutation and 
improve the functional status of ATP6[1] mutant flies. DSP1 is a Drosophila gene that belongs 
to the High-Mobility Group Box (HMGB) family, and it has been shown that HMGB1 regulates 
heat shock protein beta-1 (HSPB1), which in turn regulated mitophagy after mitochondrial injury 
in vitro [315]. The mating scheme and transgenic strains are listed in Figure 11, Figure 12, and 
Figure 13 for PGC1-α, AMPK, and DSP1, respectively. 
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 Figure 11. Generation of Transgenic Fly Strain with Nucleus-Encoded ATP6 and 
PGC-1α Overexpression. 
Mating scheme to generate experimental group animals. FM0, TM3, and TM6 are 
balancers and served as phenotypic markers for screening flies. 
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 Figure 12. Generation of Transgenic Fly Strain with Nucleus-Encoded ATP6 and 
AMPK Overexpression. 
Mating scheme to generate experimental group animals. SM6a, FM0, Sco, are balancers 
and served as phenotypic markers for screening flies. 
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 Figure 13. Generation of Transgenic Fly Strain with Nucleus-Encoded ATP6 and 
DSP1 Overexpression. 
Mating scheme to generate experimental group animals. FM0, TM3, and TM6 are 
balancers and served as phenotypic markers for screening animals. 
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 3.6.1.6 Strategy 6: Mitochondrial Autophagy Factor – ATG1 
ATG1 is required for autophagy [316], a process that is important for survival, regulation, and 
development. It not only degrades old and misfolded proteins and aged or dysfunctioning 
organelles but also provides nutrients and energy when the cell experiences various stressors 
[317]. The hypothesis for this strategy is that overexpressing ATG1 may decrease the number of 
defective mitochondria and increase mitochondria turnover to compensate for the degradation. 
Such overexpression may improve the functional status of ATP6[1] mutant flies. The mating 
scheme is shown in Figure 14. 
3.6.1.7 Strategy 7: Mitochondrial Protein Folding Factor – mtHSP70 
As described in the previous section “Mitochondrial Protein Import”, mtHSP70 is a member of 
the import motor component in the TIM complex [49]. mtHSP70 plays a dual role in precursor 
protein translocation and ATPase activity [318]. ATPase activity and binding of the precursor 
protein to mtHSP70 are essential for the unfolding of the precursor protein and complete protein 
translocation [319]. The hypothesis is that overexpressing mtHSP70 may help with the 
exogenous ATP6 protein translocation and this, in turn, will help improve the functional 
outcomes of the ATP6[1] mutant flies. The mating scheme and transgenic strains used are shown 
in Figure 15. 
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Figure 14. Generation of Transgenic Fly Strain with Nucleus-Encoded ATP6 and 
ATG1 Overexpression. 
Mating scheme to generate experimental group animals. FM0, TM3, and TM6 are 
balancers and served as phenotypic markers for screening animals. 
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 Figure 15. Generation of Transgenic Fly Strain with Nucleus-Encoded ATP6 and 
mtHSP70 Overexpression. 
Mating scheme to generate experimental group animals. FM0, TM3, and TM6 are 
balancers and served as phenotypic markers for screening animals. 
 
 69 
 3.6.1.8 Strategy 8: Mitochondrial Protein Insertion Factor – OXA1 
OXA1 is essential for inserting proteins from the matrix into the inner mitochondrial membrane 
[116, 117]. Given the characteristics of ATP6, it is hypothesized that nucleus-encoded ATP6 
would utilize the conservative pathway, which requires OXA1. The hypothesis for this particular 
strategy is that overexpressing OXA1 may improve the efficiency of exogenous ATP6 protein 
insertion into the inner mitochondrial membrane, facilitate ATP synthase complex formation, 
and this will improve the functional outcome of the mutant flies. The mating scheme and 
transgenic strains used are shown in Figure 16. 
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 Figure 16. Generation of Transgenic Fly Strain with Nucleus-Encoded ATP6 and 
OXA1 Overexpression. 
Mating scheme to generate experimental group animals. FM0, TM3, and TM6 are 
balancers and served as phenotypic markers for screening animals. 
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 3.6.2 Challenge 2: Endogenous Mutant ATP6 Competition 
Although the ATP synthase complex is dysfunctional, mutant ATP6 protein is still being 
translated in the mitochondria, suggesting there will be competition between the endogenous 
ATP6 protein and the exogenous ATP6 protein (Figure 17). Because the amount of endogenous 
ATP6 protein present will most likely be much higher than that of the amount of exogenous 
ATP6 protein imported, the exogenous ATP6 protein may not be incorporated into the ATP 
synthase complex successfully and in sufficient quantity to improve the lifespan and the 
locomotor function. In addition to competition, toxicity from total ATP6 protein overexpression 
could also be problematic. Therefore, a strategy to decrease the amount of endogenous ATP6 
mutant protein may be necessary.  
3.6.2.1 Strategy 9: Utilizing Translational Inhibitors (TLIs) 
The Palladino lab has recently designed and developed a mitochondrial-targeted RNA expression 
system (mtTRES) that expresses small chimeric RNAs that function as translational inhibitors 
(TLIs). It consists four components: 1) RNA Polymerase (RNAP) III promoter; 2) Non-coding 
leader sequence (NCL), a structured RNA or portion thereof that is expressed in the nucleus but 
is found readily within the mitochondria (5S rRNA, MRP or RNP); 3) a sequence that is 
complementary to the endogenous mRNA to prevent the docking of the mitochondrial ribosome; 
and 4) the RNAP III termination element (Figure 18). This system has been tested with three 
different NCLs (5s, MRP, RNP) and two different target sequences (ATP6 and CoxII) and 
effectively decreases the translation of endogenous proteins (Towheed et al., submitted). We will 
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be utilizing the mtTRES ATP6-TLI system in conjunction with our allotopic ATP6 expression to 
determine whether this will improve the function of our allotopic constructs.  The mating scheme 
and transgenic strains used are shown in Figure 19. 
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 Figure 17. Endogenous Mutant ATP6 Protein Expression Levels. 
ATP6 protein levels measured in WT flies (denoted as ATP6+ and sesB+), 
ATP6[1];sesB[1], ATP6[1], and sesB[1] flies by Western Blot. ATP6 protein level was 
normalized to Sod2, a mitochondrial protein, as loading control. (A) Representative Western 
Blot. (B) Quantitative analysis of normalized ATP6 expression levels from WT and ATP6 
mutant flies. Figure was produced by Dr. Alicia Celotto and permission was granted to be used 
in this dissertation. 
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 Figure 18. RNA-based mitochondrial Translational Inhibitor (TLI) approach.  
(A) Mitochondria-targeted RNA expression TLI system (mTRES) vector used to knock 
down endogenous mutant ATP6 expression. (B) The four components of the TLI construct. 
RNAP III initiation (orange) and termination sequences (brown), non-coding leader sequence 
(NCL) (blue), and anti-sense RNA (green), which is complementary to the target mRNA. (C) 
TLI functions by preventing the docking of mitochondrial ribosomes and decreasing the rate of 
translation. (D) The structures of the two NCLs, MRP and RNP, used in this experiment. Figure 
used with permission from Towheed et al. (submitted).  
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 Figure 19. Generation of Transgenic Fly Strain with Nucleus-Encoded ATP6 and 
Translational Inhibitor (TLI).  
Mating scheme to generate experimental group animals. FM0, TM3, and TM6 are 
balancers and served as phenotypic markers for screening animals. 
 
 76 
4.0  MATERIALS AND METHODS 
Drosophila melanogaster Stocks and Maintenance Drosophila stocks were maintained on 
standard cornmeal molasses fly media. ATP6[1] mutants were isolated from a sesB[1] 
background [271]. The absence of such mutation would be denoted as either sesB[+] or simply 
[+]. Virgin ATP6[1];sesB[1] was mated to male daGal4 and homozygous animals 
ATP6[1];sesB[1];;daGal4 were collected after sequence confirmation. 
ATP6[1];sesB[1];;daGal4 was the main stock used throughout our experiments. All stocks were 
obtained from Bloomington Stock Center unless indicated otherwise. PGC-1α was obtained 
from Dr. David Walker, UCLA. Canton S flies are used as WT. All of the UASB-TGs were 
maintained in homozygous states and flipped on a regular schedule. 
 
Engineering Transgenic Constructs The pUASTattB (UASB) transgenesis system was utilized 
[320]. A modified pUASTattB strain was generated so that all of the constructs could be 
generated from a few precursor clones (Figure 20). The accession numbers of all MTSs and 
UTRs were listed (Table 2-3). Full-length transgene cDNA was PCR amplified and cloned into 
pUASB to generate pUASB-TG at the attB site. 
 
Drosophila Transgenesis The vector bearing engineered ATP6 construct underwent site-directed 
PhiC31 mediated attP/B transgenesis (Figure 21). For all of the transgenes, the attp18 insertion 
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site was used except OXA1, which utilized VK00027 attP, and mtHSP70, which utilized attP2. 
The attp18 insertion site is located on the first chromosome. VK00027 and attp2 are located on 
the third chromosome. Genetic Services was used for DNA injection (Cambridge, MA, USA) 
and successfully transgenesis was identified through the presence of whitemc+. 
 
Translational Inhibitor (TLI) Expression in Transgenic Flies. RNA complementary to the 
endogenous ATP6 sequence was designated as TLI. TLI was expressed to prevent the docking of 
mitochondrial ribosomes and decrease the translation of endogenous ATP6 proteins. Two TLI 
constructs using MRP or RNP elements, were tested and each was expressed in transgenic flies in 
conjunction to the expression of algal ATP6 gene. Both MRP and RNP were inserted at the 
VK00027 attp site on chromosome 3. The TLI-MRP::ATP6 sequence is 
AGAAGCGTATCCCGCTGAGCGAAAATAAATTTGTTATCATTTTCA and the TLI-
RNP::ATP6 sequence is TCTCCCTGAGCTTCAGGGAGGAAAATAAATTTGTTAT-
CATTTTCA. The underlined sequence is the respective noncoding leader sequence (NCL) and 
the rest is the ATP6 complementary sequence. RNP is noted as RNaseP in Figure 38. VK00027 is 
abbreviated as VK27 when used in genotypes and figures in this dissertation. 
ATP6[1];sesB/+;;VK27/daGal4 and ATP6[1];NoCrAO/sesB;;VK27/daGal4 were used as 
controls when compared to ATP6[1];NoCrAO/sesB;;MRP/daGal4 and 
ATP6[1];NoCrAO/sesB;;RnaseP/daGal4, the test strains with expression of both algal ATP6 
transgene and the TLI. 
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 Figure 20. Generation of UAS Constructs. 
Determining the optimal transgenic construct of MTS, recoded ATP6, and 3’UTR for 
allotopic expression. pUAST-attB transgenesis system and Phi31 integrase system was used to 
allow transgenes be inserted in identical sites (attp). The promoter UAS was activated by 
established Gal4 lines such as daughterless-Gal4 or ubiquitous-Gal4. (A) Different MTSs (red) 
combined with recoded ATP6 (purple) and 3’UTR (yellow) to form different transgenic fly 
strains. s.o. is suboptimally-encoded. (B) Unique cloning sites were designed so all these 
different transgenes could be generated from a few initial clones. Figure usage was granted by 
Dr. Michael Palladino. 
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 Figure 21. attP/B Transgenesis with PhiC31 Integrase. 
Transgenesis involves integration using a specific attP site on chromosome. Once the 
transgene was integrated it remains at the site stably because the hybrid site cannot undergo 
integrase-catalyzed mobilization. Figure modified from Fish MP, Groth AC, Calos MP, Nusse R. 
Nat Protoc. 2007;2(10):2325-31 [321]. 
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 Analysis of ATP6 Polypeptide Sequences ATP6 protein sequences of Homo sapiens, Mus 
musculus, Drosophila melanogaster, Aedes aegypti, and Chlamydomonas reinhardtii were 
obtained from NCBI Protein Database. The sequences were aligned with software DNASTAR 
MegAlign (Version 9.10 (109) Intel) by Clustal W method. 
 
Lifespan and Behavioral Analysis Flies were collected under light carbon dioxide-induced 
anesthesia within 24 hours of eclosion and were kept on standard cornmeal molasses medium at 
a density of ~15 animals per vial. All flies were kept at a humidified, temperature-controlled 
incubator at either 25°C or 29°C. Flies were transferred to fresh vials every other day and scored 
for death. Lifespan was analyzed by Log-Rank Test (Prism V5.0b). ~ 45 animals per genotype 
were used to complete lifespan test. Mechanical sensitivity / stress test was assayed by vortexing 
the flies on a tabletop vortexer (Vortex Genie 2, Scientific Industries, Inc. New York, USA) in a 
standard vial for 20 seconds [322, 323]. The recovery time was measured as the time between the 
end of the vortexing treatment and the first normal movement (walking forward). The recovery 
time was capped at a maximum of 300 seconds. Stress tests were performed on Day 16 and Day 
20 for animals housed at 25°C and on Day 8 and Day 12 for animals housed at 29°C. 1-way 
ANOVA (Kruskal-Wallis Test) was used for statistical analysis within group. Dunn’s Multiple 
Comparison Test was used to determine the statistical significance of the recovery time of each 
genotype. 
 
Strobe Light Test The protocol has been published in [209] and is excerpted here. Flies were 
recoded using PAX-it version 6 software (Midwest Information Systems, InC. Villa Park, IL) 
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through a PAXCAM (camera) mounted on a ZEISS dissection microscope (W.E.L. Instrument 
Co). Flies were transferred from food vials to new 35mm petri dish and were allowed to rest for 
20 minutes before filming. Flies were recorded for 5 minutes before they were subjected to 
strobe lighting (SHIMPO, Itasca, IL) at a frequency of 1450 flashes per minute for 20 seconds. 
Filming continued for 5 minutes after strobe light treatment. Video analysis was performed using 
iMovie (Apple, Cupertino, CA). The recovery time was measured as the time between the end of 
the strobe light treatment and the first normal locomotor activity (i.e. walking forward or 
grooming). A two-tailed Mann-Whitney U test was used for statistical analysis at day 25. 
 
Western Blot for Algal-Drosophila Chimeras Five thoraces of each genotype (CH1S, CH2S, 
CH3S, CH4S, CH5S, NoCrAO and Canton-S wild type) were collected and homogenized in 
100ul denaturing SDS buffer. The homogenized solution was heated to 98°C for 10 minutes and 
30ul were loaded onto a 12% SDS-page gel. The proteins were transferred to a 0.2um PVDF 
transfer membrane (Millipore, MA, USA) and then blocked with a 1% PBS-Tween-Milk 
solution for 2 hours. The membrane was then incubated with 1:2000 rabbit anti-fly ATP6 
primary antibody, which was generated using purified HKEFKTLLGPSGHNGS peptide 
(NEOBioSci, MA, USA) overnight for 16 hours. The membrane was washed before incubating 
with 1:5000 goat-anti-rabbit secondary antibody (Biorad, USA) for two hours. The membrane 
was washed, incubated with ECL chemiluminescent substrate for detection of HRP (Pierce, 
Thermo Scientific, Illnois, USA), and developed. Mouse-anti-Drosophila β-tubulin primary 
antibody (1:4000) (Santa Cruz Biotechnology, Texas, USA) was used as a loading control. 
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Mitochondria Purification This procedure was modified from a published protocol [324]. Forty 
dissected thoraces per genotype were collected and homogenized with a plastic pestle in cold 
mitochondrial isolation medium (MIM: 250mM sucrose, 10mM Tris-HCl, 0.15mM MgCl2, pH 
7.4) with protease inhibitor mix. The homogenized mixture was centrifuged at 500xg at 4°C for 
5 minutes twice to remove debris. The supernatant was then centrifuged at 5000xg for 5 minutes 
to form a pellet containing mitochondria. The pellet was washed or resuspended in either a 
denaturing SDS buffer for Western Blot or an assay buffer for ATP synthase assay. 
 
ATP Synthase Assay. The procedure was modified from the protocol as described in [325] 
and.[326]. Briefly, 200 whole flies were homogenized using 40ml glass dounce tissue grinders 
(Kimble Chase Kontes, Fisher Scientific). Cellular debris was removed by centrifuging at 1300g 
x 5 minutes. Mitochondria were pelleted by 20,000g x 10 minutes. Ficoll gradient (15%, 23%, 
and 50%) was used to isolate mitochondria and spinned at 30,700g for 6 minutes. The 
mitochondria were permeabilized by digitonin and energized by ADP, malate, and puryvate. A 
luceferin and luciferase-based assay was used to determine ATP synthase activity. 
 
Statistical Analysis. Statistical software Prism Pad version 5 was used to conduct all statistical 
analyses. Lifespan was analyzed by Log-Ranked Test. Mechanical stress test was analyzed by 
one-way ANOVA (Kruskal-Wallis test). Dunn’s Multiple Comparison Test was used to 
determine the statistical significance of the recovery time of each genotype. 
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5.0  RESULTS 
5.1 PHENOTYPIC CHARACTERLIZATION OF ATP6[1] MUTANT ANIMALS 
Our goal was to determine if allotopic expression of ATP6 would rescue the mutant ATP6[1] 
animals. To that end, we utilized functional outcomes such as lifespan and stress test recovery 
time to evaluate the efficacies of our strategies against hydrophobicity and endogenous mutant 
ATP6 competition. The lifespan of mutant female ATP6[1];sesB[1]/+;;daGal4 and WT female 
ATP6[+];sesB[1]/+;;daGal4 were examined (Figure 22). The average lifespan for 
ATP6[1];sesB[1]/+;;daGal4 was 23 days and the average lifespan for 
ATP6[+];sesB[1]/+;;daGal4 female was 89 days. Upon stress test, the mean recovery time for 
mutant female was 221 seconds on Day 16 and 294 seconds on Day 20 while the mean recovery 
time for WT female was 9 seconds on Day 16 and 5 seconds on Day 20 (Figure 23). To examine 
the effect of strobe light on the behaviors of ATP6[1];sesB[1]/+;;daGal4 and 
ATP6[+];sesB[1]/+;;daGal4, the animals were subjected to strobe light stimulation for 20 
seconds and the recovery time was measured. The average recovery time at Day 5, Day 13, and 
Day 20 was comparable between ATP6[1];sesB[1]/+;;daGal4 and 
ATP6[+];sesB[1]/+;;daGal4, but a significant difference between the two genotypes was 
observed on Day 25 (Figure 24). Convulsive and paralytic behaviors were observed in 
ATP6[1];sesB[1]/+;;daGal4 but not in ATP6[+];sesB[1]/+;;daGal4 on Day 25. Videos of 
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behavioral analysis under strobe light stimulations are available at 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0025823 
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 Figure 22. Lifespan of ATP6[1] Mutants and ATP6[+] WT Incubated at 25ºC. 
The lifespan for mutants is shown in red and the lifespan for WT is shown in green. 
Median survival for ATP6[1] mutants = 23 days; n=53. Median survival for WT = 89 days; 
n=45. p<0.0001, Log-rank test.  
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 Figure 23. Mechanical Stress Test Recovery Time of ATP6[1] Mutants and ATP6[+] 
WT. 
Flies were incubated at 25ºC and mechanical stress tests were conducted on (A) day 16 
and (B) day 20. The mechanical stress test recovery time for mutants is shown in red and for WT 
shown in green. Average recovery time on day 16 was 221 seconds for ATP6[1] mutants (n= 16) 
and 9 seconds for WT (n=15); p<0.0001, unpaired t-test. Average recovery time on day 20 was 
294 seconds for ATP6[1] mutants (n=10) and 5 seconds for WT (n=14); p<0.0001, unpaired t-
test. 
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 Figure 24. Strobe Light Recovery Time of ATP6[1] Mutants and ATP6[+] WT. 
Flies were incubated at 25ºC and tested on the designated post-eclosion day. The strobe 
light recovery time of ATP6[1] mutants is shown in red and the strobe light recovery time of WT 
is shown in green. p<0.0001 on day 25, unpaired t-test. 
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 5.2 STRATEGY 1: ALGAL ATP6 SUBUNIT 
Functional Assays for Full-Length Algal Transgenic Flies 
The hypothesis for strategy 1 was that expressing algal ATP6 protein would lead to improvement 
in the functional assays of ATP6[1] mutant flies because algal ATP6 protein was naturally 
imported from the cytosol to the mitochondria. Transgenic male flies with NoCrAV, NoCrAS, or 
NoCrAO were mated to either virgin female ATP6[1];sesB[1];;daGal4 or virgin female 
ATP6[1];ubiGal4. Their female offspring were used for functional assays. 
ATP6[1];attp18/sesB[1];;daGal4 and ATP6[1];attp18;ubiGal4 were used as controls for flies 
driven by daGal4 and flies driven by ubiGal4, respectively. The lifespan and stress test for 
transgenic flies driven with daGal4 are shown in Figure 25 and Table 6-8. All three algal 
transgenic fly strains showed significant increase in lifespan at 25°C and improved recovery time 
on day 16 at 25°C. Transgenic strain NoCrAO performed the best as it also showed a significant 
increase in lifespan at 29°C and improved stress test recovery time on day 20 at 25°C and day 12 
at 29°C. The lifespan and stress test for transgenic flies driven with ubiGal4 are shown in Table 
9-11. Transgenic flies driven by ubiGal4 exhibited recurrent seizure-like activities after initial 
recovery post-mechanical stress test, making it difficult to ascertain accurate recovery time. 
Therefore, transgenic flies driven by daGal4 were used for the follow-up experiments in strategy 
1. 
 
Functional Assays for Algal –Drosophila Chimera ATP6 Flies 
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Because transgenic flies with algal transgenes displayed improved lifespan and stress test 
recovery time, we were interested in determining the crucial regions of the algal and fly ATP6 
proteins that provide phenotypic improvements. We generated five algal-Drosophila chimera 
transgenic strains (Figure 26A). Functional assays were performed (Figure 26B-E, Table 12-15). 
All the algal-chimera transgenic strains had significantly improved lifespan at 25°C and 29°C. 
Importantly, flies with CH2S, CH4S, and especially CH5S algal-chimera transgenes had 
significantly longer lifespan comparing to full-length NoCrAS. Three of the five algal-chimera 
transgenic strains had significantly decreased stress test recovery time on day 16 at 25°C and all 
five had significantly decreased test recovery time on day 20 at 25°C.  
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 Figure 25. Functional Assays for Flies Expressing Full-Length Algal Transgenes. 
Lifespan and mechanical stress test recovery time of Drosophila with nuclear-encoded 
algal ATP6 transgenes driven by daughterless-Gal4 (daGal4). Lifespan of transgenic flies 
incubated at (A) 25ºC and (B) 29ºC. Mechanical stress test recovery time at 25ºC on (C) day 16 
and (D) day 20. at 29ºC on (E) day 8 and (F) day 12. 
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 Table 6. Lifespan of algal Transgenic Flies driven by daughterless-Gal4. 
p-value was measured by Log-rank Test and compared to 
ATP6[1];attp18/sesB[1];;daGal4 (control).   
 
Code Maximum Lifespan Median Lifespan % of Control N p-value 
25°C 
attp18 33 29 - 49 - 
NoCrAV 37 33 114% 46 <0.0001 
NoCrAS 37 31 107% 45 <0.0001 
NoCrAO 39 35 121% 45 <0.0001 
29°C 
attp18 17 15 - 45 - 
NoCrAV 17 15 0% 50 0.0013 
NoCrAS 15 15 0% 45 0.0194 
NoCrAO 19 17 113% 45 <0.0001 
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 Table 7. Mechanical Stress Test Recovery Time of Algal Transgenic Flies Driven by 
daughterless-Gal4 at 25°C. 
 
One-way ANOVA Kruskal-Wallis Test and Dunn’s Multiple Comparison Test were used 
to determine the specific p-value of each transgene against ATP6[1];attp18/sesB[1];;daGal4 
control. 
 
Code Recovery Time SE % of Control N p-value <0.05? 
Day 16 at 25°C  
attp18 168.2 5.8 - 17 - 
NoCrAV 72.8 6.8 43% 16 Yes 
NoCrAS 75.5 7.0 45% 15 Yes 
NoCrAO 79.0 6.5 47% 15 Yes 
Day 20 at 25°C 
attp18 221.0 0.17 - 9 - 
NoCrAV 193.6 5.7 88% 16 No 
NoCrAS 181.1 8.5 82% 15 No 
NoCrAO 104.6 7.9 47% 15 Yes 
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 Table 8. Mechanical Stress Test Recovery time of Algal Transgenic Flies Driven by 
daughterless-Gal4 at 29°C. 
One-way ANOVA Kruskal-Wallis Test and Dunn’s Multiple Comparison Test were used 
to determine the specific p-value of each transgene against ATP6[1];attp18/sesB[1];;daGal4 
control. 
 
Code Recovery Time SE % of Control N p-value <0.05 
Day 8 at 29°C  
attp18 62.6 6.1 - 16 - 
NoCrAV 46.1 5.6 74% 16 No 
NoCrAS 46.6 5.0 74% 16 No 
NoCrAO 44.8 7.5 72% 16 No 
Day 12 at 29°C 
attp18 262.7 7.5 - 16 - 
NoCrAV 164.1 8.7 62% 15 Yes 
NoCrAS 251.9 10.8 96% 15 No 
NoCrAO 169.7 13.3 65% 16 Yes 
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Table 9. Lifespan of Algal Transgenic Flies Driven by ubiquitous-Gal4. 
p-value was measured by Log-rank Test and compared to ATP6[1];attp18;ubiGal4 
(control). 
 
Code Maximum Lifespan Median Lifespan % of Control N p-value 
25°C 
attp18 39 37 - 47 - 
NoCrAV 43 38 103% 46 0.0003 
NoCrAS 41 37 0% 45 0.0093 
NoCrAO 45 41 111% 47 <0.0001 
29°C 
attp18 21 19 - 45 - 
NoCrAV 21 17 89% 50 <0.0001 
NoCrAS 19 17 89% 46 <0.0001 
NoCrAO 21 19 100% 44 ns 
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Table 10. Mechanical Stress Test Recovery Time of Algal Transgenic Flies Driven 
by ubiquitous-Gal4 at 25°C. 
One-way ANOVA Kruskal-Wallis Test and Dunn’s Multiple Comparison Test were used 
to determine the specific p-value of each transgene against ATP6[1];attp18;ubi-Gal4 control. 
 
Code Recovery Time SE % of Control N p-value <0.05? 
Day 16 at 25°C  
attp18 101.4 12.1 - 16 - 
NoCrAV 53.4 4.2 53% 16 Yes 
NoCrAS 37.1 6.7 37% 16 Yes 
NoCrAO 59.3 4.9 58% 16 No 
Day 20 at 25°C 
attp18 146.2 4.0 - 16 - 
NoCrAV 104.2 8.6 71% 16 Yes 
NoCrAS 79.4 9.3 54% 16 Yes 
NoCrAO 93.8 10.5 64% 16 Yes 
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Table 11. Mechanical Stress Test Recovery Time of Algal Transgenic Flies Driven 
by ubiquitous-Gal4 at 29°C. 
One-way ANOVA Kruskal-Wallis Test and Dunn’s Multiple Comparison Test were used 
to determine the specific p-value of each transgene against ATP6[1];attp18;ubi-Gal4 control. 
 
Code Recovery Time SE % of Control N p-value <0.05? 
Day 8 at 29°C  
attp18 15.3 2.9 - 16 - 
NoCrAV 11.7 3.1 76% 16 No 
NoCrAS 23.2 4.2 152% 16 No 
NoCrAO 11.4 4.5 75% 16 No 
Day 12 at 29°C 
attp18 167.7 17.7 - 10 - 
NoCrAV 96.8 9.0 58% 16 Yes 
NoCrAS 82.9 7.8 49% 16 Yes 
NoCrAO 70.6 6.5 42% 16 Yes 
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 Figure 26. Constructs of Algal Chimeras and Functional Assays 
(A) Five algal chimeric transgenes were generated to determine the crucial region that led 
to functional outcome improvements. Lifespan of transgenic flies at (B) 25ºC and  (C) 29ºC. 
Mechanical stress test recovery time on (D) day 16 and (E) day 20 at 25ºC. 
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Table 12. Lifespan of Algal Chimera Transgenic Flies Driven by daughterless-Gal4 
at 25°C. 
p-value was measured by Log-rank Test and compared to 
ATP6[1];attp18/sesB[1];;daGal4 (control). 
 
Code Maximum Lifespan Median Lifespan % of Control N p-value 
attp18 33 29 - 48  
CH1S 35 32 110% 42 <0.0001 
CH2S 37 33 114% 45 <0.0001 
CH3S 39 31 107% 47 <0.0001 
CH4S 39 35 121% 45 <0.0001 
CH5S 39 37 128% 42 <0.0001 
NoCrAS 37 31 107% 45 <0.0001 
NoAS 33 29 100% 43 0.0041 
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Table 13. Lifespan of Algal Chimera Transgenic Flies Driven by daughterless-Gal4 
at 29°C. 
p-value was measured by Log-rank Test and compared to 
ATP6[1];attp18/sesB[1];;daGal4 (control). 
 
Code Maximum Lifespan Median Lifespan % of Control N p-value 
attp18 17 15 - 45  
CH1S 17 17 113% 46 <0.0001 
CH2S 17 15 100% 41 0.0006 
CH3S 19 17 113% 43 <0.0001 
CH4S 19 17 113% 49 <0.0001 
CH5S 19 17 113% 45 <0.0001 
NoCrAS 15 15 100% 45 0.0194 
NoAS 17 15 100% 48 0.1426 
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Table 14. Mechanical Stress Test Recovery Time of Algal Chimera Transgenic Flies 
Driven by daughterless-Gal4 on Day 16 at 25°C. 
One-way ANOVA Kruskal-Wallis Test and Dunn’s Multiple Comparison Test were used 
to determine the specific p-value of each transgene against ATP6[1];attp18/sesB[1];;daGal4 
control. 
 
Code Day 16 SE % of Control N p-value <0.05? 
attp18 168.2 5.8 - 17 - 
CH1S 139.8 13.5 83% 15 ns 
CH2S 152.1 17.2 90% 15 ns 
CH3S 94.5 16.4 56% 15 Yes 
CH4S 74.8 11.1 44% 16 Yes 
CH5S 104.4 9.1 62% 16 Yes 
NoCrAS 75.5 7.0 45% 15 Yes 
NoAS 87.1 16.7 52% 15 Yes 
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Table 15. Mechanical Stress Test Recovery Time of Algal Chimera Transgenic Flies 
Driven by daughterless-Gal4 on Day 20 at 25°C. 
One-way ANOVA Kruskal-Wallis Test and Dunn’s Multiple Comparison Test were used 
to determine the specific p-value of each transgene against ATP6[1];attp18/sesB[1];;daGal4 
control. 
 
Code Day 20 SE % of Control N p-value 
attp18 221 0.17 - 9 - 
CH1S 158.1 9.5 72% 15 Yes 
CH2S 168.0 10.6 76% 15 Yes 
CH3S 161.8 9.3 73% 16 Yes 
CH4S 164.4 12.4 74% 17 Yes 
CH5S 128.8 6.6 58% 16 Yes 
NoCrAS 181.1 8.5 82% 15 No 
NoAS 182.3 3.4 82% 6 No 
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 Production of Algal-Chimera ATP6 Protein 
Western Blot was attempted to determine the amount of algal-chimera ATP6 protein imported 
into mitochondria. Because the custom-made anti-ATP6 antibody could not distinguish 
endogenous ATP6 protein from engineered ATP6 protein, we had to rely on the possible 
difference in size between the endogenous ATP6 protein and the transgenic algal ATP6 protein. 
The hypothesis was that the MTS cleavage sites for algal-chimera ATP6 and the endogenous 
ATP6 were different. If that was correct, then there should be two bands on the Western Blot. 
However, only one band was detected. It is possible that 1) the amount of exogenous algal-
chimera ATP6 protein was too low to be detected, especially when the endogenous ATP6 protein 
was still produced at a normal level and 2) the size difference between algal-chimera ATP6 
protein and the endogenous ATP6 protein was too small to be detected at this resolution. 
5.3 STRATEGY 2: MITOCHONDRIAL TARGETING SEQUENCES 
The hypothesis for strategy 2 was that an addition of exogenous MTS to the recoded Drosophila 
ATP6 protein would lead to increased import efficiency and improvements in functional assays. 
We have generated 18 transgenic UASB-TG fly strains (5 MTSs x 3 3’UTRs and No-exogenous 
MTSs x 3 3’UTRs) driven by two different Gal4 systems (daughterless-Gal4 and ubiquitous-
Gal4) and incubated at two different conditions (25ºC and 29ºC). Of all the transgenic fly strains, 
PAS, PAO, and sOAS gave the best overall performance (Figure 27). However, the functional 
improvements were not as dramatic as those of algal fly strains. While transgenic flies with 
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different MTS performed significantly better than the control, none of them consistently 
performed better than the others. The complete results are listed in tabular forms (Table 16-27).  
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Figure 27. Functional Assays to Determine the Best Transgenic Constructs 
(A) Lifespan assays for the best three non-algal fly strains at 25ºC. Transgenic flies with 
PAS, PAO, and sOAS have longer lifespan than the ATP6[1];attp18 mutant control. Mechanical 
stress test recovery time on (B) day 16 and (C) day 20 at 25ºC. *** = p<0.0001 
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Table 16. Lifespan of Transgenic Fly Strains Driven by daughterless-Gal4 at 25ºC. 
p-value was measured by Log-rank Test and compared to 
ATP6[1];attp18/sesB[1];;daGal4 (control). 
 
Code Max lifespan Median Lifespan % of Control N p-value 
attp18 33 29  - 49  
SAO 35 33 114% 45 <.0001 
8AV 35 33 114% 42 <.0001 
8AO 35 33 114% 43 <.0001 
DAO 35 32 110% 48 <.0001 
PAV 33 31 107% 43 <.0001 
PAS 35 31 107% 49 <.0001 
sOAV 35 31 107% 45 <.0001 
sOAS 33 31 107% 45 <.0001 
sOAO 33 31 107% 48 <.0001 
DAV 33 31 107% 45 <.0001 
NoAO 33 31 107% 42 <.0001 
SAV 31 29 100% 49 0.6137 
SAS 35 29 100% 45 .0003 
PAO 35 29 100% 46 .0002 
DAS 33 29 100% 45 .1557 
8AS 31 29 100% 45 .7703 
NoAV 33 29 100% 43 .006 
NoAS 31 29 100% 45 .0055 
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Table 17. Lifespan of Transgenic Fly Strains Driven by daughterless-Gal4 at 29ºC. 
p-value was measured by Log-rank Test and compared to 
ATP6[1];attp18/sesB[1];;daGal4 (control). 
 
Code Max lifespan Median Lifespan % of Control N p-value 
attp18 17 15  - 45  
PAS 19 17 113% 45 <.0001 
DAO 17 17 113% 50 <.0001 
8AO 19 17 113% 45 <.0001 
PAV 17 15 100% 45 0.2383 
PAO 19 15 100% 50 0.3618 
sOAV 15 15 100% 49 0.0045 
sOAS 17 15 100% 45 0.0383 
sOAO 17 15 100% 46 0.012 
SAV 17 15 100% 45 0.0004 
SAS 17 15 100% 45 0.9468 
SAO 17 15 100% 45 0.4452 
DAV 17 15 100% 45 0.0076 
8AV 19 15 100% 45 0.0066 
8AS 17 15 100% 55 0.0178 
NoAV 17 15 100% 47 0.0492 
NoAS 19 15 100% 48 0.1426 
NoAO 17 15 100% 43 0.5892 
DAS 17 13 87% 45 <.0001 
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Table 18. Lifespan of Transgenic Fly Strains Driven by ubiquitous-Gal4 at 25ºC. 
p-value was measured by Log-rank Test and compared to ATP6[1];attp18;ubiGal4 
(control). 
 
Code Max lifespan Median Lifespan % of Control N p-value 
attp18 39 37  - 47  
sOAO 43 41 111% 48 <.0001 
DAO 43 41 111% 45 <.0001 
8AO 43 41 111% 44 <.0001 
PAV 43 39 105% 47 <.0001 
PAS 43 39 105% 46 <.0001 
sOAS 43 39 105% 45 <.0001 
SAV 43 39 105% 45 <.0001 
8AV 41 39 105% 44 <.0001 
NoAS 43 39 105% 45 <.0001 
NoAO 43 39 105% 44 <.0001 
8AS 41 38 103% 30 .0111 
PAO 41 37 100% 44 0.0021 
sOAV 41 37 100% 47 0.2741 
SAS 43 37 100% 44 0.0042 
SAO 45 37 100% 45 <.0001 
DAV 41 37 100% 45 0.01 
DAS 41 37 100% 45 0.5901 
NoAV 41 37 100% 44 0.0062 
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Table 19. Lifespan of Transgenic Fly Strains Driven by ubiquitous-Gal4 at 29ºC. 
p-value was measured by Log-rank Test and compared to ATP6[1];attp18;ubiGal4 
(control). 
 
Code Max lifespan Median Lifespan % of Control N p-value 
attp18 21 19  - 45  
SAS 23 21 110% 49 0.0706 
PAS 21 19 100% 45 0.4884 
sOAS 21 19 100% 47 <.0001 
sOAO 21 19 100% 45 0.0071 
SAV 21 19 100% 42 <.0001 
SAO 21 19 100% 50 0.0008 
DAV 21 19 100% 48 0.0004 
DAO 23 19 100% 45 0.0668 
8AV 21 19 100% 45 0.0016 
8AO 21 19 100% 45 0.2822 
NoAS 21 19 100% 45 0.0013 
NoAO 21 19 100% 45 0.9366 
PAV 19 17 90% 46 <.0001 
PAO 19 17 90% 44 <.0001 
sOAV 21 17 90% 44 <.0001 
DAS 21 17 90% 41 <.0001 
8AS 19 17 90% 45 <.0001 
NoAV 21 17 90% 46 <.0001 
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Table 20. Mechanical Stress Test Recovery Time for Transgenic Fly Strains Driven 
by daughterless-Gal4 at 25ºC on Day 16. 
Transgenic fly strains were grouped by MTS for One-way ANOVA Kruskal-Wallis Test. 
Dunn’s Multiple Comparison Test were used to determine the specific p-value of each transgene 
against ATP6[1];attp18/sesB[1];;daGal4 control. 
 
Code Day 16 SE % of Control N p-value 
attp18 168.2 5.8  - 17  
PAO 69.75 5.7 41% 16 *** 
SAO 74.19 6.9 44% 16 *** 
DAV 73.88 10.6 44% 16 *** 
NoAS 87.07 16.7 52% 15 *** 
NoAO 89.94 9.0 53% 16 *** 
PAS 89.13 3.9 53% 16 *** 
sOAS 90.19 2.8 54% 16 *** 
sOAO 91.5 8.0 54% 16 *** 
8AO 92.38 4.6 55% 16 *** 
DAS 96.75 11.1 58% 16 *** 
SAV 99.13 3.9 59% 16 *** 
SAS 98.75 8.5 59% 16 *** 
8AV 102.1 8.1 61% 15 *** 
PAV 107.3 8.0 64% 16 ** 
NoAV 109.6 11.0 65% 15 ** 
DAO 118.8 12.2 71% 16 ** 
8AS 140.7 9.7 84% 15 ns 
sOAV 149.2 8.1 88% 16 ns 
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Table 21. Mechanical Stress Test Recovery Time for Transgenic Fly Strains Driven 
by daughterless-Gal4 at 25ºC on Day 20. 
Transgenic fly strains were grouped by MTS for One-way ANOVA Kruskal-Wallis Test. 
Dunn’s Multiple Comparison Test were used to determine the specific p-value of each transgene 
against ATP6[1];attp18/sesB[1];;daGal4 control. 
 
Code Day 20 SE % of Control N p-value 
attp18 221 0.0  - 9  
sOAS 114.7 7.3 52% 16 *** 
DAS 139.2 6.4 63% 16 *** 
SAO 144.8 7.4 66% 16 *** 
sOAO 158.3 6.1 72% 16 ** 
DAO 166.6 11.8 75% 8 ** 
PAV 167.6 6.2 76% 16 *** 
NoAS 182.3 3.4 82% 6 *** 
SAV 188.8 3.4 85% 16 * 
PAO 190.3 8.4 86% 16 ** 
DAV 192 3.8 87% 16 ns 
8AO 194 9.4 88% 16 * 
SAS 196.6 7.9 89% 16 ns 
NoAO 199.9 7.4 90% 15 * 
NoAV 203.4 4.6 92% 15 * 
PAS 205.7 5.8 93% 16 ns 
8AV 216 6.2 98% 16 ns 
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Table 22. Mechanical Stress Test Recovery Time for Transgenic Fly Strains Driven 
by daughterless-Gal4 at 29ºC on Day 8. 
Transgenic fly strains were grouped by MTS for One-way ANOVA Kruskal-Wallis Test 
Dunn’s Multiple Comparison Test were used to determine the specific p-value of each transgene 
against ATP6[1];attp18/sesB[1];;daGal4 control. 
 
Code Day 8 SE % of Control N p-value 
attp18 62.56 6.1  - 16  
PAO 6 3.7 10% 16 *** 
PAS 15.79 3.2 25% 14 ** 
sOAS 20.63 6.0 33% 16 ** 
PAV 23.38 8.3 37% 16 * 
DAV 31.75 7.5 51% 16 ns 
SAO 41.07 7.2 66% 14 ns 
NoAS 42 7.2 67% 15 ns 
sOAO 46.73 8.1 75% 15 ns 
DAO 55.63 7.6 89% 16 ns 
8AO 60.31 8.4 96% 16 ns 
SAV 60.63 5.7 97% 16 ns 
sOAV 61.69 6.5 99 16 ns 
SAS 63.88 6.2 102% 16 ns 
8AS 68.69 7.8 110% 16 ns 
NoAV 70 4.7 112% 16 ns 
8AV 71.13 8.3 114% 16 ns 
DAS 79.25 5.5 127% 16 ns 
NoAO 80.69 6.6 129% 16 * 
 
 112 
Table 23. Mechanical Stress Test Recovery Time for Transgenic Fly Strains Driven 
by daughterless-Gal4 at 29°C on Day 12. 
Transgenic fly strains were grouped by MTS for One-way ANOVA Kruskal-Wallis Test. 
Dunn’s Multiple Comparison Test were used to determine the specific p-value of each transgene 
against ATP6[1];attp18/sesB[1];;daGal4 control. 
 
Code Day 12 SE % of Control N p-value 
attp18 262.7 7.5  - 16  
sOAS 130.9 9.5 50% 15 *** 
8AO 150.8 6.2 57% 16 *** 
DAO 160.8 3.3 61% 16 *** 
PAS 161.7 7.7 62% 13 *** 
PAO 162.9 8.9 62% 14 *** 
8AV 162.8 5.8 62% 16 *** 
sOAO 166.6 2.2 63% 15 *** 
sOAV 171.2 16.8 65% 16 *** 
NoAV 176.6 17.3 67% 16 *** 
NoAO 184.7 4.8 70% 16 *** 
DAS 184.5 3.1 70% 15 ** 
SAO 186.3 5.2 71% 14 *** 
DAV 191.3 7.1 73% 14 *** 
SAV 193.2 6.8 74% 15 *** 
8AS 209.3 5.7 80% 16 ns 
NoAS 214.1 6.2 81% 15 ** 
PAV 217.2 8.9 83% 15 ns 
SAS 222.5 8.3 85% 15 * 
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Table 24. Mechanical Stress Test Recovery Time for Transgenic Fly Strains Driven 
by ubiquitous-Gal4 at 25ºC on Day 16. 
Transgenic fly strains were grouped by MTS for One-way ANOVA Kruskal-Wallis Test. 
Dunn’s Multiple Comparison Test were used to determine the specific p-value of each transgene 
against ATP6[1];attp18;ubiGal4 control. 
 
Code Day 16 SE % of Control N p-value 
attp18 101.4 12.1  - 16  
PAV 21.06 5.4 21% 16 *** 
PAS 29.56 8.0 29% 16 *** 
SAS 33.83 8.5 33% 12 *** 
SAO 33.75 5.7 33% 16 *** 
SAV 34.21 6.1 34% 14 *** 
8AV 35.38 7.2 35% 16 *** 
NoAS 36.31 7.6 36% 16 *** 
DAV 39.38 5.6 39% 16 *** 
sOAO 39.69 6.1 39% 16 *** 
PAO 46.81 4.9 46% 16 * 
DAO 53.75 4.8 53% 16 ** 
8AO 59.53 7.5 59% 15 * 
sOAS 61.53 2.9 61% 15 ns 
DAS 65.93 4.4 65% 15 ns 
NoAV 70.31 3.4 69% 16 ns 
8AS 79.07 10.4 78% 15 ns 
sOAV 80.31 16.4 79% 16 ns 
NoAO 83.38 4.3 82% 16 ns 
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Table 25. Mechanical Stress Test Recovery Time for Tansgenic Fly Strains Driven 
by ubiquitous-Gal4 at 25ºC on Day 20. 
Transgenic fly strains were grouped by MTS for One-way ANOVA Kruskal-Wallis Test. 
Dunn’s Multiple Comparison Test were used to determine the specific p-value of each transgene 
against ATP6[1];attp18;ubiGal4 control. 
 
Code Day 20 SE % of Control N p-value 
attp18 146.2 4.0  - 16  
PAV 65.06 12.1 45% 16 *** 
SAO 70.31 4.5 48% 16 *** 
8AV 79.38 14.0 54% 16 *** 
SAS 80.5 5.5 55% 12 *** 
SAV 84.64 8.5 58% 14 *** 
DAS 88.87 4.7 61% 15 *** 
PAS 90.56 5.5 62% 16 *** 
PAO 92.63 6.7 63% 16 *** 
sOAO 94.25 6.6 64% 16 *** 
DAV 95.06 6.1 65% 16 *** 
8AO 104.4 9.0 71% 16 ** 
sOAS 114.4 7.7 78% 16 ** 
sOAV 119.1 3.7 81% 16 ** 
DAO 120.8 11.2 83% 16 * 
NoAS 151 15.4 103% 15 ns 
NoAO 170.3 4.5 116% 16 ns 
8AS 212.7 14.7 145% 7 ns 
NoAV 225.7 8.3 153% 16 *** 
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Table 26. Mechanical Stress Test Recovery Time for Transgenic Fly Strains Driven 
by ubiquitous-Gal4 at 29ºC on Day 8. 
Transgenic fly strains were grouped by MTS for One-way ANOVA Kruskal-Wallis Test. 
Dunn’s Multiple Comparison Test were used to determine the specific p-value of each transgene 
against ATP6[1];attp18;ubiGal4 control. 
 
Code Day 8 SE % of Control N p-value 
attp18 15.25 2.9  - 16  
PAS 6.75 0.7 44% 14 ns 
PAV 11.75 3.2 77% 16 ns 
DAV 13.31 3.0 87% 16 ns 
SAO 13.56 3.7 89% 16 ns 
sOAO 15.2 2.6 100% 15 ns 
NoAS 15.69 3.3 103% 16 ns 
PAO 19.44 4.7 127% 16 ns 
8AO 19.81 3.8 130% 16 ns 
8AV 21.81 4.5 143% 16 ns 
sOAV 22.31 4.7 146% 16 ns 
sOAS 23.75 5.1 156% 16 ns 
DAO 27.25 5.8 179% 16 ns 
SAS 31.19 6.4 205% 16 ns 
DAS 36.63 8.8 240% 16 ns 
SAV 39.21 4.2 257% 14 ** 
NoAO 40.08 5.2 263% 16 ** 
NoAV 42.25 3.8 277% 16 *** 
8AS 57.25 6.3 375% 16 *** 
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Table 27. Mechanical Stress Test Recovery Time for Transgenic Fly Strains Driven 
by ubiquitous-Gal4 at 29ºC on Day 12. 
Transgenic fly strains were grouped by MTS for One-way ANOVA Kruskal-Wallis Test. 
Dunn’s Multiple Comparison Test were used to determine the specific p-value of each transgene 
against ATP6[1];attp18;ubiGal4 control. 
 
Code Day 12 SE % of Control N p-value 
attp18 167.7 17.7  - 10  
SAV 57.15 4.0 34% 13 *** 
PAS 63.63 4.9 38% 16 *** 
SAO 71.13 9.0 42% 16 ** 
sOAS 74.06 3.9 44% 16 *** 
SAS 74.73 5.3 45% 15 * 
sOAV 83.5 7.7 50% 16 ** 
PAO 89.31 7.1 53% 16 ** 
sOAO 89 8.5 53% 15 * 
8AO 92.69 10.1 55% 16 *** 
PAV 99.69 5.1 59% 16 ns 
8AV 103 7.3 61% 16 ** 
DAV 111 11.9 66% 16 ** 
NoAS 121.3 8.9 72% 15 * 
NoAO 122.9 5.1 74% 14 ** 
DAS 124.9 8.6 74% 15 * 
NoAV 127.2 5.9 76% 15 ** 
8AS 136.3 10.2 81% 16 ns 
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 5.4 STRATEGY 3: SOD2 3’UTR OR OXA1 3’UTR 
Because SOD2 3’UTR and OXA1 3’UTR were tested along with different MTS, the results were 
shown in tabular form above. The hypothesis for strategy 3 was that by attaching SOD2 3’UTR 
or OXA1 3’UTR to the C-terminus of the recoded ATP6 gene the mRNA would be brought 
closer to the mitochondrial surface, facilitating protein import and improving functional assay 
performances. Although many transgenic fly strains with SOD2 3’UTR and OXA1 3’UTR 
performed better than the control (SV40 3’UTR), neither performed consistently better than the 
other. 
5.5 STRATEGY 4: SUBOPTIMALLY-ENCODED CODONS 
Suboptimally-encoded transcripts are translated more slowly and, thus, may allow for increased 
co-tranlsational import and improved efficiency of import with less toxicity resulting from 
cytosolic aggregation. The hypothesis for strategy 4 was that better synchronization of 
translation and import would lead to improved functional assay outcomes. Five pairs of 
transgenic fly strains with regular recoded codons and suboptimally-encoded codons were tested 
(Figure 28). (A) The difference in lifespan between SAO and SsoAO is not significant 
(p=0.082). (B) Transgenic fly strain with regular recoded codons SAS has a significantly longer 
lifespan than that with suboptimally-encoded codons SsoAS (p<0.0001). (C) Fly strain with 
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suboptimally encoded codons DsoAS has a significantly longer lifespan than that with regular 
recoded codons DAS (p<0.0032). (D) The difference in lifespan between DAO and DsoAO is 
not significant (p=0.95). (E) Transgenic fly strain with regular recoded codons NoAS has a 
significantly longer lifespan than that with suboptimally-encoded codons (NosoAS) (p<0.0013). 
There was no consistent trend to show that transgenic fly strains with suboptimally-encoded 
codons performed better than those with regular recoded codons. 
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 Figure 28. Lifespan of Transgenic Fly Strains with Suboptimally-Encoded ATP6. 
Transgenic fly strains with regular recoded codons are shown in red and those with 
suboptimally-encoded codons are shown in black. All flies were incubated at 25ºC. (A) SAO vs. 
SsoAO. (B) SAS vs. SsoAS. (C) DAS vs. DsoAS. (D) DAO vs. DsoAO and (E) NoAS vs. 
NosoAS. 
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5.6 STRATEGY 5: MITOCHONDRIAL BIOGENESIS FACTORS 
The best performing transgenic strains in strategy 1 and 2 (NoCrAO, PAS, PAO and sOAS) were 
chosen to further test whether the overexpression of mitochondrial biogenesis factors (PGC1-α, 
AMPK, and DSP1) would improve functional outcomes. The hypothesis for this strategy was 
that overexpressing AMPK or PGC1-α would increase the total number of mitochondria through 
activation of nuclear respiratory factor -1, -2 and estrogen-related receptor- α, which induce 
genes that encode mitochondrial proteins [327]. This might help overcome the energy deficits 
caused by the ATP6 mutation and improve the functional status of ATP6[1] mutant flies.  
Overexpression of PGC1-α at 25ºC (Figure 29) led to decreased lifespan in NoCrAO fly 
strain (A). The median lifespan did not show improvement for (B) PAS and (D) sOAS when 
PGC1-α was overexpressed. The median lifespan did increase for (C) PAO with PGC1-α 
overexpression when compared to the PAO strain by 7% but it was not statistically significant. 
At 29ºC, overexpressing PGC1-α did not improve median survival for all four transgenic strains 
tested (Figure 30). For mechanical stress tests, transgenic fly strains with PGC1-α 
overexpression consistently performed worse than those without PGC1-α overexpression (Figure 
31 and 32). 
Overexpression of AMPK at 25ºC (Figure 33) led to decreased lifespan in NoCrAO fly 
strain (A). The median lifespans for PAS, PAO, and sOAS showed statistically significant 
increase when AMPK was overexpressed (B-D). Overexpression of AMPK at 29°C (Figure 34) 
led to increased median lifespan in PAO and sOAS but not in NoCrAO and PAS. For mechanical 
stress tests, transgenic fly strains with AMPK overexpression performed worse than those 
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without AMPK overexpression (Figure 35 and 36) except in the cases of PAS and PAO at 29°C 
(Figure 36 B and C). 
Attempts to generated transgenic flies with DSP1 overexpression were not successful 
because virgin ATP6[1];FM0/UAS-TG;;TM6/daGal4 exhibited reduced viability and sufficient 
animals could not be obtained.   
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 Figure 29. Lifespan of Transgenic Fly Strains with Nucleus-Encoded ATP6 and 
Overexpression of PGC1-α at 25ºC.  
Transgenic fly strains with (A) NoCrAO, (B) PAS, (C) PAO, and (D) sOAS. 
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 Figure 30. Lifespan of Transgenic Fly Strains with Nucleus-Encoded ATP6 and 
Overexpression of PGC1-α at 29ºC. 
Transgenic fly strains with (A) NoCrAO, (B) PAS, (C) PAO, and (D) sOAS. 
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 Figure 31. Mechanical stress test recovery time of transgenic strains with nucleus-
encoded ATP6 and overexpression of PGC1-α at 25ºC on Day 16. 
Transgenic fly strains with (A) NoCrAO, (B) PAS, (C) PAO, and (D) sOAS. 
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 Figure 32. Mechanical Stress Test Recovery Time for Transgenic Fly Strains with 
Nucleus-Encoded ATP6 and Overexpression of PGC1-α at 25ºC on Day 20. 
Transgenic fly strains with (A) NoCrAO, (B) PAS, (C) PAO, and (D) sOAS. 
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 Figure 33. Lifespan of Transgenic Fly Strains with Nucleus-Encoded ATP6 and 
Overexpression of AMPK at 25ºC. 
Transgenic fly strains with (A) NoCrAO, (B) PAS, (C) PAO, and (D) sOAS. 
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 Figure 34. Lifespan of Transgenic Fly Strains with Nucleus-Encoded ATP6 and 
Overexpression of AMPK at 29ºC. 
Transgenic fly strains with (A) NoCrAO, (B) PAS, (C) PAO, and (D) sOAS. 
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 Figure 35. Mechanical Stress Test Recovery Time of Transgenic Fly Strains with 
Nucleus-Encoded ATP6 and Overexpression of AMPK at 25ºC on Day 16. 
Transgenic fly strains with (A) NoCrAO, (B) PAS, (C) PAO, and (D) sOAS. 
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 Figure 36. Mechanical Stress Test Recovery Time of Transgenic Fly Strains with 
Nucleus-Encoded ATP6 and Overexpression of AMPK at 25ºC on Day 20. 
Transgenic fly strains with (A) NoCrAO, (B) PAS, (C) PAO, and (D) sOAS. 
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5.7 STRATEGY 6: MITOCHONDRIAL AUTOPHAGY FACTOR 
The hypothesis for this strategy was that overexpressing ATG1 might decrease the number of 
defective mitochondria and promote mitochondria turnover to compensate for the degradation, 
improving the efficacy of a rescue.  ATG1 overexpression is known to increase autophagy and is 
protective for PINK1 pathogenesis [328]. We examined overexpression of ATG1; however, no 
larva were observed on the medium, suggesting that broadly-expressed ATG1 in Drosophila is 
developmentally lethal. We did not pursue this avenue of investigation further. 
5.8 STRATEGY 7: MITOCHONDRIAL PORTEIN FOLDING FACTOR 
mtHSP70 is a critical mitochondrial chaperone involved in stabilizing hydrophobic proteins and 
assisting their import into the inner mitochondrial membrane. The hypothesis for this strategy 
was that overexpressing mtHSP70 might stabilize and assist nucleus-encoded ATP6 protein 
import. Double transgenic ATP6[1] flies with both UAS-TG and UAS-mtHSP70 were generated, 
driven by daGAL4, and incubated at 25ºC and at 29ºC to test for rescue. No significant 
differences in functional assays (lifespan and stress test recovery time) were observed (Table 28-
30). 
 131 
Table 28. Lifespan of Transgenic Fly Strains with Nucleus-Encoded ATP6 and 
Overexpression of mtHSP70 at 25ºC. 
Genotype Max Lifespan Median Lifespan N 
ATP6[1];sesB[1]/+;;attp2/daGal4 37 35 49 
ATP6[1];attp18/sesB[1];;daGal4 35 31 47 
ATP6[1];sesB[1]/+;;mtHSP70/daGal4 33 29 48 
ATP6[1];NoCrAV/sesB[1];;daGal4 39 37 46 
ATP6[1];NoCrAV/sesB[1];;mtHSP70/daGal4 35 31 44 
ATP6[1];NoCrAS/sesB[1];;daGal4 37 33 48 
ATP6[1];NoCrAS/sesB[1];;mtHSP70/daGal4 33 31 45 
ATP6[1];NoCrAO/sesB[1];;daGal4 39 35 44 
ATP6[1];NoCrAO/sesB[1];;mtHSP70/daGal4 35 31 46 
ATP6[1];PAV/sesB[1];;daGal4 33 31 43 
ATP6[1];PAV/sesB[1];;mtHSP70/daGal4 35 31 44 
ATP6[1];PAS/sesB[1];;daGal4 35 31 49 
ATP6[1];PAS/sesB[1];;mtHSP70/daGal4 33 31 45 
ATP6[1];PAO/sesB[1];;daGal4 35 29 46 
ATP6[1];PAO/sesB[1];;mtHSP70/daGal4 33 29 51 
ATP6[1];sOAS/sesB[1];;daGal4 33 31 45 
ATP6[1];sOAS/sesB[1];;mtHSP70/daGal4 33 31 44 
ATP6[1];sOAO/sesB[1];;daGal4 33 31 48 
ATP6[1];sOAO/sesB[1];;mtHSP70/daGal4 33 31 45 
ATP6[1];SAS/sesB[1];;daGal4 35 29 45 
ATP6[1];SAS/sesB[1];;mtHSP70/daGal4 33 31 43 
ATP6[1];SAO/sesB[1];;daGal4 35 33 45 
ATP6[1];SAO/sesB[1];;mtHSP70/daGal4 33 29 47 
ATP6[1];8AS/sesB[1];;daGal4 31 29 45 
ATP6[1];8AS/sesB[1];;mtHSP70/daGal4 33 31 42 
ATP6[1];8AO/sesB[1];;daGal4 35 33 43 
ATP6[1];8AO/sesB[1];;mtHSP70/daGal4 33 31 42 
ATP6[1];NoAS/sesB[1];;daGal4 31 29 45 
ATP6[1];NoAS/sesB[1];;mtHSP70/daGal4 33 31 43 
ATP6[1];NoAO/sesB[1];;daGal4 33 31 42 
ATP6[1];NoAO/sesB[1];;mtHSP70/daGal4 33 29 48 
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Table 29. Lifespan of Transgenic Fly Strains with Nucleus-Encoded ATP6 and 
Overexpression of mtHSP70 at 29ºC.  
Genotype Max Lifespan Median Lifespan N 
ATP6[1];sesB[1]/+;;attp2/daGal4 17 15 48 
ATP6[1];attp18/sesB[1];;daGal4 17 15 45 
ATP6[1];sesB[1]/+;;mtHSP70/daGal4 15 15 23 
ATP6[1];NoCrAV/sesB[1];;daGal4 17 17 42 
ATP6[1];NoCrAV/sesB[1];;mtHSP70/daGal4 17 15 51 
ATP6[1];NoCrAS/sesB[1];;daGal4 19 15 46 
ATP6[1];NoCrAS/sesB[1];;mtHSP70/daGal4 17 15 44 
ATP6[1];NoCrAO/sesB[1];;daGal4 21 17 45 
ATP6[1];NoCrAO/sesB[1];;mtHSP70/daGal4 17 15 47 
ATP6[1];PAV/sesB[1];;daGal4 17 15 45 
ATP6[1];PAV/sesB[1];;mtHSP70/daGal4 15 15 43 
ATP6[1];PAS/sesB[1];;daGal4 19 17 45 
ATP6[1];PAS/sesB[1];;mtHSP70/daGal4 15 13 44 
ATP6[1];PAO/sesB[1];;daGal4 19 15 45 
ATP6[1];PAO/sesB[1];;mtHSP70/daGal4 15 13 45 
ATP6[1];sOAS/sesB[1];;daGal4 17 15 45 
ATP6[1];sOAS/sesB[1];;mtHSP70/daGal4 15 15 51 
ATP6[1];sOAO/sesB[1];;daGal4 17 15 46 
ATP6[1];sOAO/sesB[1];;mtHSP70/daGal4 15 13 56 
ATP6[1];SAS/sesB[1];;daGal4 17 15 45 
ATP6[1];SAS/sesB[1];;mtHSP70/daGal4 15 15 49 
ATP6[1];SAO/sesB[1];;daGal4 17 15 45 
ATP6[1];SAO/sesB[1];;mtHSP70/daGal4 15 13 48 
ATP6[1];8AS/sesB[1];;daGal4 17 15 55 
ATP6[1];8AS/sesB[1];;mtHSP70/daGal4 17 15 44 
ATP6[1];8AO/sesB[1];;daGal4 19 17 45 
ATP6[1];8AO/sesB[1];;mtHSP70/daGal4 15 15 48 
ATP6[1];NoAS/sesB[1];;daGal4 19 15 48 
ATP6[1];NoAS/sesB[1];;mtHSP70/daGal4 15 15 50 
ATP6[1];NoAO/sesB[1];;daGal4 17 15 43 
ATP6[1];NoAO/sesB[1];;mtHSP70/daGal4 15 13 45 
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Table 30. Mechanical Stress Test Recovery Time of Transgenic Strains with 
Nucleus-Encoded ATP6 and Overexpression of mtHSP70 on Day 16 at 25ºC. 
Genotype Mean SE N 
ATP6[1];sesB[1]/+;;attp2/daGal4 101.7 4.7 15 
ATP6[1];attp18/sesB[1];;daGal4 112.2 10.8 14 
ATP6[1];sesB[1]/+;;mtHSP70/daGal4 123.1 6.9 13 
ATP6[1];NoCrAV/sesB[1];;daGal4 95.9 2.1 17 
ATP6[1];NoCrAV/sesB[1];;mtHSP70/daGal4 85.7 8.0 16 
ATP6[1];NoCrAS/sesB[1];;daGal4 104.1 3.8 17 
ATP6[1];NoCrAS/sesB[1];;mtHSP70/daGal4 77.9 5.8 17 
ATP6[1];NoCrAO/sesB[1];;daGal4 69.1 5.3 18 
ATP6[1];NoCrAO/sesB[1];;mtHSP70/daGal4 76.1 4.0 15 
ATP6[1];PAV/sesB[1];;daGal4 107.2 8.0 16 
ATP6[1];PAV/sesB[1];;mtHSP70/daGal4 70.4 7.8 16 
ATP6[1];PAS/sesB[1];;daGal4 89.1 3.9 16 
ATP6[1];PAS/sesB[1];;mtHSP70/daGal4 85.4 9.7 14 
ATP6[1];PAO/sesB[1];;daGal4 69.8 5.7 16 
ATP6[1];PAO/sesB[1];;mtHSP70/daGal4 101.9 9.3 16 
ATP6[1];sOAS/sesB[1];;daGal4 90.2 2.8 16 
ATP6[1];sOAS/sesB[1];;mtHSP70/daGal4 79.1 3.1 14 
ATP6[1];sOAO/sesB[1];;daGal4 91.5 8.0 16 
ATP6[1];sOAO/sesB[1];;mtHSP70/daGal4 119.9 15.3 14 
ATP6[1];SAS/sesB[1];;daGal4 98.8 8.5 16 
ATP6[1];SAS/sesB[1];;mtHSP70/daGal4 73.7 6.8 15 
ATP6[1];SAO/sesB[1];;daGal4 77.9 5.0 16 
ATP6[1];SAO/sesB[1];;mtHSP70/daGal4 69.5 5.0 16 
ATP6[1];8AS/sesB[1];;daGal4 140.4 9.1 16 
ATP6[1];8AS/sesB[1];;mtHSP70/daGal4 96.5 5.0 15 
ATP6[1];8AO/sesB[1];;daGal4 92.4 4.6 16 
ATP6[1];8AO/sesB[1];;mtHSP70/daGal4 99.9 3.1 15 
ATP6[1];NoAS/sesB[1];;daGal4 87.1 16.7 15 
ATP6[1];NoAS/sesB[1];;mtHSP70/daGal4 88.3 2.9 15 
ATP6[1];NoAO/sesB[1];;daGal4 89.9 9.0 16 
ATP6[1];NoAO/sesB[1];;mtHSP70/daGal4 105.7 7.6 15 
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 5.9 STRATEGY 8: MITOCHONDRIAL PROTEIN INSERTION FACTOR 
OXA1 is known to be a critical protein for inner mitochondrial membrane insertion. The 
hypothesis was that overexpressing OXA1 would improve the efficiency of insertion and 
improve efficacy of allotopic expression in vivo. Double transgenic ATP6[1] strains with both 
UAS-TG and UAS-OXA1 were generated, driven by daGAL4, and incubated at 25°C for testing 
(Figure 37). Transgenic strains with overexpression of OXA1 showed malformed wings and 
significantly shorter lifespan, possibly due to toxicity (Figure 37). 
 135 
 Figure 37. Lifespan of Transgenic Strains With Nucleus-Encoded ATP6 and 
Overexpression of OXA1 at 25ºC. 
Transgenic fly strains with different algal ATP6 transgenes, with and without the 
overexpression of OXA1. 
 
5.10 STRATEGY 9: TRANSLATIONAL INHIBITORS (TLIs) 
It is known the ATP6[1] mutants express a stable mutant protein bearing the glycine to glutamate 
substitution. As ATP6 is a critical component of a complex and elaborately assembled multi-
subunit ATP synthase, it is likely that allotopically expressed wild type protein will be in 
competition for inclusion in the mature synthase complex.  Flies expressing TLI-MRP::ATP6 or 
TLI-RNP::ATP6 have been shown to reduce steady state expression of the endogenous ATP6 
protein.  We examined whether TLI-MRP::ATP6 or TLI-RNP::ATP6 expression along with the 
NoCrAO transgene showed significantly increased lifespan and decreased mechanical stress test 
recovery time (Figure 38). Notice that NoCrAO fly strain with a VK27 background did not show 
a statistically significant improvements in lifespan and mechanical stress test recovery time 
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comparing to ATP6[1] mutants in a VK27 background. This was in contrast to NoCrAO 
transgenic fly strain in attp18 background, which showed significantly improvement in 
functional assays comparing to ATP6[1] mutants in an attp18 background. 
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 Figure 38. Functional Assays for Transgenic Flies Expressing NoCrAO transgene 
and TLI. 
(A) Lifespan of transgenic flies expressing algal ATP6 transgene (NoCrAO) with MRP or 
RNP showed significantly improvement comparing to NoCrAO alone or MRP or RNP alone. (B) 
Transgenic flies with NoCrAO with TLI expression showed significantly decreased mechanical 
stress test recovery time. 
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6.0  DISCUSSION 
The task of examining the efficacy of ATP6 allotopic expression in an animal model has never 
been undertaken before. We examined 9 strategies and found that utilizing algal ATP6 subunit 
delivered the best functional results while other strategies provided limited improvements. 
 
Drosophila is an excellent animal model for screening because 1) it is relatively easy to 
generate transgenic animals and proper genetic controls; 2) they have short life cycles (~14 days) 
and relatively short lifespans; and 3) they can be generated in large numbers. In this project, we 
utilized more than 30 transgenic strains driven by 2 Gal4 systems at two different temperatures. 
It would have been much more difficult to do that in a mammalian model. The phenotypes of the 
ATP6[1] mutant models mirror closely those of human patients, which allow us to infer that if 
we could achieve phenotypic rescue in Drosophila it would not be unreasonable to expect similar 
functional improvements in humans. As stated earlier, the ATP6[1] mutant flies have 98% 
heteroplasmy, which is higher than any viable organism documented. This provides a very 
rigorous model to test the efficacy of allotopic expression but also makes it much more 
challenging to show a positive phenotypic rescue. For example, if we had a fly model with a 
90% heteroplasmy and we were able to import 5% engineered ATP6 protein into the 
mitochondria, it might be sufficient to alleviate the severity of the phenotype (in humans, 70-
90% ATP6 heteroplasmy leads to NARP while 90%+ ATP6 heteroplasmy leads to MILS, a much 
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more severe disease). However, being able to import 5% engineered ATP6 protein into the 
mitochondria might not be sufficient in our flies because they had a 98% heteroplasmy. Flies 
with a 93% heteroplasmy might show similar phenotypes as those with a 98% heteroplasmy. 
Therefore, a much higher percentage of engineered ATP6 import is required to show any rescue 
effect. 
 
Because it was a large-scale screening effort, we focused on using daughterless-GAL4 
and ubiquitous-GAL4, both broadly-expressed promoters, to drive our transgenic constructs. 
Although daughterless-GAL4 and ubiquitous-GAL4 are commonly used, their expression 
profiles are not entirely well-described. Most importantly, their expression levels tend to 
fluctuate during development, adulthood, and aging, so the transcription levels may vary, 
affecting translation and the amount of engineered ATP6 proteins actually generated. Although 
daughterless-GAL4 and ubiquitous-GAL4 are both broadly-expressed, the flies driven by 
ubiquitous-GAL4 tend to live longer than those driven by daughterless-GAL4. The reason is 
unknown. It is also unclear why transgenic animals driven by ubiquitous-GAL4 tend to 
experience recurrent seizures after initial recovery post mechanical stress test. However, it does 
point out the importance of examining different GALl4 systems and determining one that is most 
suitable for the experiments on hand. The importance of tissue-specific GAL4 system will 
become obvious when we discuss overexpressing factors that are involved in various 
mitochondrial functions. 
 
The background of the animals is also of significance. As pointed out in figure 38, flies 
expressing algal ATP6 in a VK27 background did not show any rescue effect comparing to 
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ATP6[1] mutants in a VK27 background. However, significant improvements in functional 
assays were achieved in flies expressing algal ATP6 in an attp18 background comparing to 
ATP6[1] mutants in an attp18 background. Also, the median lifespan for female offspring that 
had a paternal parent from an attp18 background was longer than the median lifespan for female 
offspring that had a paternal parent from a Canton S background (29 days vs. 23 days), even 
though the maternal parents from both matings were identical (ATP6[1];sesB;;daGal4). This 
highlighted the importance of utilizing suitable controls and testing multiple fly lines. 
 
We incubated the animals at two different temperatures at 25°C and 29°C. Increasing the 
temperature will increase the metabolism and speed up the life cycle of Drosophila. However, a 
compressed life cycle may mask a moderate rescue, and the stress response induced by increased 
temperature may alter protein expression and functions. When we evaluated the transgenic 
animals, we did realize that the transgenic fly strains that performed best at 25°C might not be 
the same ones that performed best at 29°C. 
  
Stress tests were performed on day 16 and day 20 for flies that were incubated at 25°C 
and on day 8 and day 12 for flies that were incubated at 29°C. Because ATP6[1] mutant 
phenotypes are progressive, with mechanical stress test and strobe light test recovery times 
comparable to those of WT flies when they are young, it is essential to determine an optimal time 
during their adulthood to perform stress test assays. Day 16 and day 20 were reasonable choices 
as many of the transgenic fly strains showed significantly improved recovery time comparing to 
the control. The optimal time also depends on the GAL4 that is driving the transgene. For 
example, most stress tests conducted on day 8 for the flies driven by ubiquitous-GAL4 did not 
 141 
show significant differences comparing to the control, suggesting that the flies, on day 8, had not 
entered their symptomatic phase yet. Moreover, the stress test recovery time for 8-day-old flies 
incubated at 29°C did not necessarily correspond to that for 16-day-old flies incubated at 25°C. 
There was a 4-day gap between the two successive stress tests at both temperatures. However, 
because the flies had a compressed life cycle at 29°C, the physiology of the flies on day 12 at 
29°C most likely would be very different from that of the flies on day 20 at 25°C. 
 
Another challenge associated with performing behavioral assays in animals is the 
variability. Changes in seasons, slight variations in humidity and temperature in the incubators, 
conditions of the medium, the time of the day when the tests are conducted can all introduce 
variables into the functional outcomes. Care has been taken as much as possible to maintain a 
constant environment for the animals and minimize these variables, but it is still possible that the 
fluctuations in the environment and experimental treatment may affect functional test 
performances. 
 
Despite the challenges, we also obtained some exciting results. Of all the strategies 
tested, it was somewhat surprising that algal ATP6 subunit delivered the best functional 
outcome. Because the rest of the ATP synthase originated from Drosophila, an algal ATP6 
subunit might not fit properly into the rest of the complex. Indeed, although one of the transgenic 
strains showed a 21% increase in lifespan comparing to that of the ATP6[1];attp18 control, it 
was still significantly shorter than the lifespan of WT animals (Figure 39). Further improvements 
in functional tests were observed in algal-chimera transgenic animals (CH5S delivered a 28% 
increase in lifespan). A reasonable explanation was that all the algal-chimera utilized the same 
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algal MTS and the algal MTS provided a similar advantage for all the engineered ATP6 proteins 
(full-length algal ATP6 or algal-chimera ATP6) to be imported into mitochondria. Once inside 
the mitochondria, however, the algal-chimera ATP6 protein may assemble in and/ or function 
within the mature complex better than the full-length algal ATP6 protein. We were limited in our 
ability to map such critical domains due to the number of chimeras examined. We sought to 
determine the relative amount of full-length algal and algal-chimera ATP6 proteins imported into 
the mitochondria. Unfortunately, there was no commercially available ATP6 antibody against 
Chlamydomonas reinhardtii, and our custom-made anti-ATP6 antibody could not distinguish 
endogenous and engineered ATP6 protein. We tried to circumvent this by exploiting a possible 
difference in size between the MTS-processed algal-chimera ATP6 protein and the endogenous 
Drosophila ATP6 protein, as the recognition epitope of the custom-made anti-ATP6 antibody 
was also present in the algal-chimera ATP6 proteins. We expected that would lead to two bands 
of different sizes on a Western Blot. However, the cleavage site of the algal MTS was predicted 
to be 107aa [279] and the size of the MTS-processed algal-chimera ATP6 would be 25.6kDa, 
which was very similar in size to the endogenous Drosophila ATP6 protein 26.4kDa. We were 
able to observe only one band in Western Blot. This could be due to several reasons. The sizes of 
the MTS-processed algal ATP6 and the endogenous ATP6 were similar and thus we were not 
able to differentiate them at this resolution. Another possibility was that the amount of algal 
ATP6 protein that was delivered into the mitochondria was so low that it could not be observed 
on a standard Western Blot. Attaching a marker such as myc-tag would have been helpful; 
however, we could not determine a site where the myc-tag could be attached on the algal protein 
without compromising its function. However, based on the functional readouts of algal ATP6 
transgenic strains versus engineered fly ATP6 transgenic strains, it is reasonable to suggest that 
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the length and the hydrophilicity of the algal MTS were the most important factors in providing 
the rescues we observed in these experiments. 
 144 
 Figure 39. Improvement in Lifespan in ATP6[1] Mutant Flies with Algal ATP6 
Expression. 
Expression of algal ATP6 in ATP6[1] mutant flies provided statistically significant 
improvement in lifespan. Average lifespan for ATP6[1] mutant flies is 29 days.  
ATP6[1];NoCrAO;;daGal4 is 35 days, and ATP6[+];;;daGal4 is 89 days.  
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We have also attempted to perform ATP synthase activity assay. This assay provides the 
most definitive proof that the allotopically-expressed ATP6 is incorporated properly and 
functional. However, multiple protocols have been tested and we have not been able to obtain 
reproducible results. This result is hardly atypical as ATP synthase assay is very sensitive to 
protein and detergent concentration [270], and some in vitro studies of ATP6 allotopic 
expression have also failed to show improved ATP synthase activity outcome [257, 270]. 
 
When testing different MTSs and 3’UTRs, our hypothesis was that a single construct 
would be the optimal combination and provide significantly better functional readouts than the 
rest of the constructs. We would then utilize that one particular construct to test other strategies. 
However, most transgenic constructs with different MTSs and 3’UTRs delivered moderate 
improvements and none of them stood out. It was probably because none of the MTSs were as 
hydrophilic and as long as the algal MTS, and thus their potentials were limited. Moreover, the 
very hydrophobic fly ATP6 protein might be too difficult to be imported into the mitochondria 
even with exogenous MTS and 3’UTR in sufficient quantities. However, we did see 
improvements in both lifespan and mechanical stress test recovery time, so they were able to 
deliver some improvement although not at levels that we would have liked. One obvious 
question was how efficiently was engineered ATP6 protein imported into the mitochondria? 
Unfortunately, our custom Drosophila anti-ATP6 antibody could not distinguish the engineered 
ATP6 protein from the endogenous mutant ATP6 protein. It would have been useful to 
determine the efficacy of each strategy by first measuring the total engineered ATP6 proteins 
that were translated and then performing mitochondrial purification and measuring the amount of 
engineered ATP6 proteins that were imported into the mitochondria.  
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Overall, where we did get siginifcant rescues nothing came close to giving us a complete 
rescue (Figure 39).  It is likely that only a small amount of Drosophila ATP6 was imported as 
allotopic expression of human ATP6 in cybrids yields a 18.5% import efficiency [255]. 
However, it is also possible that ATP6 protein level is expressed at a very high level that it 
becomes toxic to the animals as daughterless-Gal4 is a ubiquitous promoter that is expressed in 
all tissues. We have a Drosophila anti-ATP6 antibody, however, we cannot distinguish mutant, 
wildtype or engineered forms of the protein at this time.  Non-protein-coding RNAs can affect 
transcription [329]. Primers can be designed to determine the transcription efficiency as 
measured by quantitative RT-PCR to rule out inefficient transcription. We could possibly 
distinguish between low expression and overexpression toxicity with Western blotting using 
anti-ATP6. Many possibilities exist as to what happens downstream after the nucleus-encoded 
ATP6 gene is inserted. Questions such as transcription efficiency, translation efficiency, how the 
ATP6 proteins interact with other proteins, such as heat shock proteins, in the cytosol, whether 
the engineered, hydrophobic ATP6 proteins would aggregate and be targeted for degradation, 
whether the entire ATP6 polypeptide was imported into the mitochondria instead of tethering at 
the import pore, and whether it folds into proper conformation and inserts correctly into the ATP 
synthase complex remain to be answered. 
 
Transgenic fly strains with suboptimally-encoded codons did not consistently perform 
better than the fly strains with regular recoded codons in functional assays. In theory, 
synchronizing the speed of translation and the speed of import should allow, presumably, more 
engineered ATP6 protein to be imported into the mitochondria. However, there were so many 
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factors at play such as hydrophobicity and competition from the endogenous ATP6 proteins that 
this might not even be a crucial factor. 
 
Another potential issue was that an imprecise number of ATP6 subunit was imported. As 
ATP6 synthase complex has multiple subunits, importing excessive number of ATP6 may 
interfere with proper incorporation and toxicity while lower-than-required ATP6 importation 
may not deliver optimal rescue result. Being able to quantify the amount of proteins that are 
transported into the mitochondria will be an important first step before we can control the 
amount of proteins that are imported. 
 
We sought to overexpress several factors that played important roles in mitochondrial 
functions. We examined PGC1-α, AMPK, DSP1 for their roles in mitochondrial biogenesis, 
mtHSP70 for its role in mitochondrial protein folding and unfolding, ATG1 for its role in 
autophagy, and OXA1 for its role in the conservative pathway for mitochondrial import. For 
PGC1-α, overexpressing PGC1-α led to decreased lifespan, which was consistent with a 
published report [324]. However, overexpressing PGC1-α in the digestive tract increased 
lifespan in wild type Drosophila. A follow-up on this experiment would be to utilize intestinal-
specific driver to increase PGC1-α expression in the ATP6[1] mutant flies. A caveat is that the 
mitochondrial mutation in the ATP6[1] mutant flies is present in 98% of the mitochondria that 
presents in all tissues; therefore, whether driving expression only in the intestinal tract is 
sufficient to increase lifespan is unclear. However, limiting expression with tissue specificity 
may circumvent potential toxicity. For AMPK, the literature of its effects on Drosophila is 
mixed. A report showed that overexpressing AMPK in adult fat body or adult muscles improved 
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lifespan [330], but flies that were fed with metformin, which activated AMPK, did not have 
increased longevity [331]. All our transgenic flies were driven by broadly-expressed 
daughterless-GAL4, and PAS, PAO and sOAS transgenic flies showed significant lifespan 
improvement at 25°C. Utilizing tissue-specific Gal4 may help further improve the efficacy of 
AMPK overexpression in the ATP6[1] mutants. Overexpressing DSP1 was unsuccessful due to 
the difficulty in obtaining the desired genotype. Overexpressing ATG1 is developmentally lethal 
when driven by daughterless-GAL4. Therefore, a follow-up experiment will be to limit its 
expression to muscle-specific GAL4 or neuron-specific GAL4. For mtHSP70, there was no 
significant improvement in lifespan or stress test recovery time in flies overexpressing mtHSP70. 
It could be due to tissue specificity or other factors upstream (e.g. hydrophobicity) that lowered 
the efficacy of mtHSP70 function. Flies overexpressing OXA1 showed obvious toxicity with 
significantly shortened lifespan and malformed wings. It is unclear why overexpressing OXA1 
would lead to malformation. It is possible that overexpressing OXA1 might have led to increased 
insertion of other proteins that utilized the conservative pathway and overwhelmed the import 
system. Moreover, because ATP6 does not require import under natural circumstances, we made 
the best guess that it would utilize the conservative pathway. It is possible that engineered ATP6 
utilized another pathway, but it is unlikely due to the protein characteristics that utilize each 
pathway. In conclusion, tissue-specificity seems to be a crucial determinant in overexpressing 
proteins that play roles in mitochondrial functions. 
 
 Translational Inhibitor (TLI) was developed in our lab to address another major obstacle 
with ATP6 protein import – competition between endogenous ATP6 and engineered ATP6 to get 
incorporated into the ATP synthase complex. It is an engineered RNA that is complementary to 
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the target mRNA. Once it binds to the target mRNA, it prevents the docking of the mitochondrial 
ribosomes and thus reduces translation of the target protein. In this project, we utilized two 
different non-coding leader sequences (NCLs) – MRP and RNP - to determine which one 
delivered a better outcome. We did notice that the lifespan and the mechanical stress test 
recovery time improved when flies co-expressed algal transgenes and translational inhibitors 
comparing to flies expressing algal transgenes alone. However, as stated earlier, the flies 
expressing algal transgenes in a VK27 background did not perform better than the VK27 control. 
This is different from the results we observed when the flies expressing algal transgenes were in 
attp18 background. This shows the importance of background and how it can affect phenotypic 
outcomes significantly. 
 
The most promising avenue of future research is to study MTS as a major determinant of 
import efficiency. The main difference between the algal ATP6 and the recoded Drosophila 
ATP6 was the size and hydrophilicity of the MTS and N-terminus of the nascent polypeptide. In 
yeast, using a tandem duplication of the Neurospora crassa ATPase9 MTS was sufficient to 
overcome the obstacle of importing ATP8, when a single ATPase9 MTS was not able to do so 
[332]. We could utilize a similar method (e.g. duplicate P1 MTS). However, the main obstacle - 
the hydrophobicity of the ATP6 protein – remained.  
 
Overall, algae Chlamydomonas reinhardtii ATP6 protein provides the best rescue 
efficacy to a Drosophila strain with an ATP6[1] mutation utilizing allotopic protein expression. 
Based on our results, we conclude that MTS is a major determinant of import efficiency. Other 
factors that have been shown to be efficacious in in vitro conditions provide modest 
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improvements in an in vivo animal model. Competition from the endogenous ATP6 protein can 
be effectively addressed by TLI. However, reducing ATP6 hydrophobicity will be crucial in 
facilitating ATP6 protein import into mitochondria and improving functional outcomes. One way 
to circumvent ATP6 protein hydrophobicity altogether has already been investigated: allotopic 
ATP6 RNA import. Recoded ATP6 gene is expressed in the nucleus and ATP6 mRNA is 
transcribed. However, the mRNA will be transported into the mitochondria and the 
mitochondrial translational machinery will translate the protein, and thus circumventing the 
challenge of importing a hydrophobic protein through the TIM-TOM complex. There are four 
components to this engineered ATP6 sequence, similar to the TLI construct shown in Figure 
18B, except that the antisense RNA is replaced by the recoded ATP6 mRNA sequence. The MTS 
used in this dissertation will be replaced by non-coding leader sequences such as 5s, MRP, and 
RNP. 5s rRNA is readily found in the mitochondria [333, 334], and MRP and RNP are readily 
imported into mammalian mitochondria [335]. These structural elements will target the 
engineered ATP6 mRNA into the mitochondria. This strategy has already been met with success. 
In a project headed by graduate student Atif Towheed in the Palladino lab, it has been shown that 
importing engineered ATP6 RNA and TLI leads to significantly improved lifespan and 
locomotor function (Towheed et al., manuscript in preparation). 
 
The ultimate goal of ATP6 allotopic expression research is to translate the functional 
improvements in an animal model to human patients. To this end, developing a targeted delivery 
system is necessary. For treatment of Leber’s hereditary optic neuropathy (LHON), delivery of 
ND4, also a mitochondrially-encoded gene, by Adeno-Associated Virus (AAV) has already been 
tested for efficacy and safety in the mouse system [336-338] and ex vivo primate eyes [339]. A 
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human clinical trial is underway [340, 341].  AAV can accommodate genes up to 5kb in size, and 
thus it can deliver most mitochondrial genes [338]. Although the mode of delivery of ND4 may 
apply to ATP6, there are several fundamental differences between the two mutations. Patients 
suffering visual loss from LHON usually have 100% mutant mtDNA homoplamy. This suggests 
that even a very small amount of transgene delivery to LHON patients might be sufficient to 
prevent visual loss. Moreover, ND4 delivery is narrowly targeted to the eye by injection, while 
ATP6 will potentially be delivered to multiple organs, raising the challenge of delivering the 
optimal dosage of transgene (and the translated protein) that is efficacious but non-toxic to the 
cells. 
 
Besides virus-mediated delivery system, embryonic extrapolation represents another 
potential venue in treating patients with ATP6 mutations at a very early stage. Extrapolation 
involves delivering short high-voltage pulses to temporarily permeabilize the cell membrane, 
which allows a variety of molecules, including DNA, to be imported into a cell. It is possible that 
after in vitro fertilization process that the zygote or the blastomeres be subjected to 
electroporation, allowing the recoded ATP6 transgene be delivered into the cell. The challenges 
associated with this strategy include the stability of ATP6 transgene in the cell and integration 
issue with the existing nuclear genome; however, it has been successfully demonstrated in a ND4 
rat model [342]. 
 
Because pharmacotherapy has been studied extensively but none of the drug cocktails is 
particularly promising, it is reasonable to explore gene therapy for potential cures. Overall, ATP6 
protein allotopic expression in vitro has been explored for more than a decade with conflicting 
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reports on its efficacy and feasibility, and ATP6 protein allotopic expression in vivo has only 
been explored by two labs so far (Palladino lab and Pinkert lab from Auburn University). Many 
obstacles such as hydrophobicity, localization, endogenous mutant ATP6 competition, proper 
incorporation still exist and require further investigation. However, it is highly like that with 
ATP6 RNA import and other technical developments these challenges will be overcome. 
Subsequent optimization of a delivery system in vitro and in vivo will ensue, and based on the 
example of ND4 it is believed that allotopic expression of ATP6 is a promising genetic approach 
to treating mitochondrial diseases in humans. 
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